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A B S T R A C T
Background
Early accurate detection of all skin cancer types is essential to guide appropriate management and to improve morbidity and survival.
Melanoma and squamous cell carcinoma (SCC) are high-risk skin cancers, which have the potential to metastasise and ultimately lead
to death, whereas basal cell carcinoma (BCC) is usually localised, with potential to infiltrate and damage surrounding tissue. Anxiety
around missing early cases needs to be balanced against inappropriate referral and unnecessary excision of benign lesions. Optical
coherence tomography (OCT) is a microscopic imaging technique, which magnifies the surface of a skin lesion using near-infrared
light. Used in conjunction with clinical or dermoscopic examination of suspected skin cancer, or both, OCT may offer additional
diagnostic information compared to other technologies.
Objectives
Todetermine the diagnostic accuracy ofOCT for the detection of cutaneous invasivemelanoma and atypical intraepidermalmelanocytic
variants, basal cell carcinoma (BCC), or cutaneous squamous cell carcinoma (cSCC) in adults.
Search methods
We undertook a comprehensive search of the following databases from inception up to August 2016: Cochrane Central Register of
Controlled Trials; MEDLINE; Embase; CINAHL; CPCI; Zetoc; Science Citation Index; US National Institutes of Health Ongoing
Trials Register; NIHR Clinical Research Network Portfolio Database; and the World Health Organization International Clinical Trials
Registry Platform. We studied reference lists and published systematic review articles.
Selection criteria
We included studies of any design evaluating OCT in adults with lesions suspicious for invasive melanoma and atypical intraepidermal
melanocytic variants, BCC or cSCC, compared with a reference standard of histological confirmation or clinical follow-up.
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Data collection and analysis
Two review authors independently extracted data using a standardised data extraction and quality assessment form (based on QUADAS-
2). Our unit of analysis was lesions. Where possible, we estimated summary sensitivities and specificities using the bivariate hierarchical
model.
Main results
We included five studies with 529 cutaneous lesions (282 malignant lesions) providing nine datasets for OCT, two for visual inspection
alone, and two for visual inspection plus dermoscopy. Studies were of moderate to unclear quality, using data-driven thresholds for
test positivity and giving poor accounts of reference standard interpretation and blinding. Studies may not have been representative of
populations eligible for OCT in practice, for example due to high disease prevalence in study populations, and may not have reflected
how OCT is used in practice, for example by using previously acquired OCT images.
It was not possible to make summary statements regarding accuracy of detection of melanoma or of cSCC because of the paucity
of studies, small sample sizes, and for melanoma differences in the OCT technologies used (high-definition versus conventional
resolution OCT), and differences in the degree of testing performed prior to OCT (i.e. visual inspection alone or visual inspection plus
dermoscopy).
Pooled data from two studies using conventional swept-source OCT alongside visual inspection and dermoscopy for the detection of
BCC estimated the sensitivity of OCT as 95% (95% confidence interval (CI) 91% to 97%) and specificity of 77% (95% CI 69% to
83%).
When applied to a hypothetical population of 1000 lesions at the mean observed BCC prevalence of 60%, OCT would miss 31 BCCs
(91 fewer than would be missed by visual inspection alone and 53 fewer than would be missed by visual inspection plus dermoscopy),
and OCT would lead to 93 false-positive results for BCC (a reduction in unnecessary excisions of 159 compared to using visual
inspection alone and of 87 compared to visual inspection plus dermoscopy).
Authors’ conclusions
Insufficient data are available on the use of OCT for the detection of melanoma or cSCC. Initial data suggest conventional OCT may
have a role for the diagnosis of BCC in clinically challenging lesions, with our meta-analysis showing a higher sensitivity and higher
specificity when compared to visual inspection plus dermoscopy. However, the small number of studies and varying methodological
quality means implications to guide practice cannot currently be drawn.
Appropriately designed prospective comparative studies are required, given the paucity of data comparing OCT with dermoscopy and
other similar diagnostic aids such as reflectance confocal microscopy.
P L A I N L A N G U A G E S U M M A R Y
What is the diagnostic accuracy of optical coherence tomography (OCT), an imaging test, for the detection of skin cancer in
adults?
Why is improving the diagnosis of skin cancer important?
There are several different types of skin cancer. Melanoma is one of the most dangerous forms, and it is important that it is recognised
early so that it can be removed. If it is not recognised (also known as a false-negative test result), treatment can be delayed, and this
risks the melanoma spreading to other organs in the body, which may lead to eventual death. Cutaneous squamous cell carcinoma
(cSCC) and basal cell carcinoma (BCC) are usually localised (i.e. limited to a certain part of the body) skin cancers, although cSCC
can spread to other parts of the body and BCC can cause disfigurement if not recognised early. Diagnosing a skin cancer when it is
not actually present (a false-positive result) may result in unnecessary surgery and other investigations and can cause stress and anxiety
to the patient. Making the correct diagnosis is important, and mistaking one skin cancer for another can lead to the wrong treatment
being used or lead to a delay in effective treatment.
What is the aim of the review?
The aim of this Cochrane Review was to find out how accurate optical coherence tomography (OCT) is for diagnosing skin cancer.
Researchers in Cochrane included five studies to answer this question. Two studies were concerned with the diagnosis of melanoma
and three with the diagnosis of BCC.
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What was studied in the review?
A number of tools are available to skin cancer specialists which allow a more detailed examination of the skin compared to examination
by the naked eye alone. Currently, a dermoscope is used by most skin cancer specialists, which magnifies the skin lesion (a mole or
area of skin with an unusual appearance in comparison with the surrounding skin) using a bright light source. OCT magnifies the
surface of a skin lesion to the level of that seen using a microscope using near-infrared light. It is quick to perform but is more expensive
compared to dermoscopy and requires specialist training. Review authors examined how useful OCT is to help diagnose skin cancers
when used after visual inspection or visual inspection plus dermoscopy.
What are the main results of the review?
The review included five studies: two studies with 97 participants with 133 skin lesions suspected of being melanoma, and three studies
with 305 participants with 396 lesions suspected of being BCC of which one (50 lesions) also analysed cSCCs (nine lesions).
The studies investigating the accuracy of OCT for diagnosing melanoma were small and too different from each other to allow a reliable
estimate of the accuracy of OCT for melanoma to be made. Similarly, only one small, low-quality study investigated the accuracy of
OCT for diagnosing cSCC.
For identifying BCC, two studies showed the effects of skin specialists using OCT after visual inspection alone, or visual inspection
with dermoscopic examination. These two studies indicated that in theory, if OCT were to be used in a group of 1000 people with
skin lesions that were particularly difficult to diagnose, of whom 600 (60%) actually had BCC, then:
- an estimated 662 people would have an OCT result confirming that a BCC was present and of these 93 (14%) would not actually
have had a BCC (false-positive result);
- of the 338 people with an OCT result indicating that no BCC was present, 31 (9%) would actually have a BCC (false-negative result).
Compared to making a diagnosis of BCC using visual inspection plus dermoscopy, the addition of OCT in this group would reduce
the number of false-positive results by 87 (thus reducing unnecessary surgical procedures) and would miss 53 fewer BCCs.
How reliable are the results of the studies of this review?
In all included studies, the diagnosis of skin cancer was made by lesion biopsy (OCT/dermoscopy positive) (a biopsy involves taking
a sample of body cells and examining them under a microscope), and the absence of skin cancer was confirmed by biopsy (OCT/
dermoscopy negative)*. This is likely to have been a reliable method for deciding whether people really had skin cancer. However, the
small number of studies included in this review, and variability between them, reduced the reliability of findings. Included studies also
had important limitations, in particular study participants were from more restricted groups than would be eligible for an OCT scan in
practice (e.g. all studies included people with skin lesions that had already been selected for surgical removal), while the way in which
OCT was used may not reflect real-life situations.
Who do the results of this review apply to?
Studies were conducted in Europe and the US only. Average age (reported in only two studies) was 46 years for melanoma and 63 years
for BCC. The percentage of people with a final diagnosis of melanoma was 23% and 27% (in two studies), ranged from 58% to 61%
for BCC (three studies), and was 18% for cSCC (one study). For the diagnosis of BCC, the results apply to people with ’pink’ and
non-pigmented skin lesions that the clinician considers particularly difficult to diagnose by the naked eye alone.
What are the implications of this review?
Not enough research has been done on using OCT in detecting skin cancers. The results of this review suggest that OCTmight help to
diagnose BCC when it is difficult to distinguish it from benign skin lesions, but it is not yet clear whether it can adequately distinguish
between BCC, cSCC, and melanoma skin cancers. More studies are needed comparing OCT to dermoscopy and to other microscopic
techniques (such as reflectance confocal microscopy) in well-described groups of people with suspicious skin lesions.
How up-to-date is this review?
The review authors searched for and used studies published up to August 2016.
*In these studies biopsy or clinical follow-up were the standard comparisons.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Question What is the diagnostic accuracy of OCT for the diagnosis of skin cancer in adults?
Population: Adults with skin lesions suspicious for melanoma (2/ 5) or for BCC (3/ 5). No studies recruited suf f icient numbers of cases of cSCC for inclusion
Prior test-
ing and preva-
lence:
All studies included lesions selected for excision or biopsy. There was some requirement for clinical suspicion of malignancy (1/ 2 in melanoma) and for
recruitment of only clinically challenging lesions (2/ 3 in BCC). The prevalence of melanoma was 23% to 27%; prevalence of BCC ranged f rom 58% to 61%
Settings: Secondary care and specialist cancer clinics
Target condi-
tion(s):
Invasive melanoma and atypical intraepidermal melanocyt ic variants (2); BCC (3)
Index test: Convent ional and high density OCT; diagnost ic thresholds based on subject ive assessment of OCT features with (2) and without (2) associated scoring, and
quant itat ive assessment of attenuat ion (1)
Reference
standard:
Histology
Action: If accurate, posit ive results of OCT could help to appropriately select lesions for excision and reduce mult iple biopsies in those with suspected BCC
Limitations
Risk of bias: Part icipant select ion methods unclear (3/ 5) due to lack of descript ion of recruitment methods (2) or study design (1). High risk of bias for the index test due
to lack of blinding (1/ 5) and clearly (1/ 5) or possibly (1/ 5) data-driven thresholds. Reference standard blinding was not described (5/ 5). Tim ing of index and
reference standards was not reported. Exclusions due to test failures were not reported (3/ 5) or their f inal diagnoses were not described (1/ 5). Low risk
of bias for f low and tim ing apart f rom exclusions due to missing histology (1/ 5) and failure to adequately image lesions (1/ 5). No other index test failures
mentioned
Applicability of
evidence to
question:
High (3/ 5) or unclear (1/ 5) concerns about applicability of part icipants due to unrepresentat ive part icipant samples or mult iple lesions per part icipant (1/ 5).
High concerns about applicability of index test due to image-based diagnosis (4/ 5) with blinding to all other clinical information (1/ 5) or unclear information
provided to test observers (2/ 5). Reference standard interpretat ion by experienced histopathologists not described (4/ 5)
Quantity of evidence
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Number of stud-
ies
5 Total part ici-
pants with test
resultsa
402 Total lesions with test resultsa 529 Total melanoma le-
sions
36
Total BCC lesions 237
Total cSCC lesions 9
Detection of invasive melanoma or atypical intraepidermal melanocytic variants
Number of studies Total lesions
with test results
Total lesions with melanoma
2 133 36 (32 invasive, 4 melanoma in situ)
Findings 2 studies evaluated invasive melanoma or atypical intraepidermal melanocyt ic variants:
• convent ional OCT at an attenuat ion coef f icient of 5.4 mm
¹: sensit ivity 89% (95%CI 52% to 100%) and specif icity 61% (95%CI 42% to 78%) (1/ 2);
• HD-OCT sensit ivity 74% (95%CI 54% to 89%) and specif icity 92% (95% CI 83% to 97%) using scoring system based on OCT
characterist ics (1/ 2); both melanoma in situ lesions misclassif ied as negat ive on OCT.
Detection of BCC [pooled analysisb]
Number of studies Total lesions
with test results
Total lesions with BCC
3 [2] 396 [346] 237 [208]
Pooled analyses Numbers observed in a cohort of 1000 lesions being tested (at mean prevalence 60%)c
2 studies of observer diagnosis
with VI alone, VI plus dermoscopy,
and with OCT (total n = 346; BCC
n = 208)
Sensitivity (95% CI) Specificity (95%
CI)
True positive False positive False negative True negative
(received neces-
sary excision)
(received unnecessary ex-
cision)
(did not receive re-
quired excision)
(appropriately not ex-
cised)
VI alone: 80% (55% to 93%) 37% (24% to 52%) 478 252 122 148
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VI plus
dermoscopy:
86% (76% to 92%) 55% (46% to 63%) 516
(38)
180
(72)
84
(38)
220
(72)
OCT: 95% (91% to 97%) 77% (69% to 83%) 569
(53)
93
(87)
31
(53)
307
(87)
Findings Pooled studies - results consistent between studies; conducted in clinically equivocal populat ions
Other studies (n = 1) - sim ilar results for OCT obtained using Berlin score at ≥ 8 (sensit ivity 97%, 95%CI 82% to 100%) and specif icity 76%,
95% CI 53% to 92%) with lower sensit ivity (66%, 95% CI 46% to 82%) and higher specif icity (86%, 95% CI 64% to 97%) at the higher score of
≥ 12. Unclear whether this would be replicated in usual pract ice sett ing
Detection of cSCC
Findings 1 case-control study with 9 cSCCs, total number of lesions = 50:
• poor sensit ivity for OCT obtained using Berlin score at ≥ 8 (sensit ivity 56%. 95%CI 21% to 86%) and specif icity 100%, 95%CI 91% to
100%) with lower sensit ivity (33%, 95%CI 7% to 70%) and the same specif icity (100%) at the higher score of ≥ 12. Unclear whether this
would be replicated in usual pract ice sett ing.
aAll results use lesions as the unit of analysis.
bSquared brackets indicate numbers used in pooled analysis.
cNumbers est imated at 25th, 50th (median), and 75th percent iles of BCC prevalence observed across 2 datasets report ing
evaluat ions of OCT added to dermoscopy and VI.
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CI: conf idence interval; HD-OCT: high-def init ion opt ical
coherence tomography; n: number; OCT: opt ical coherence tomography; VI: visual inspect ion.
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B A C K G R O U N D
This review is one of a series of Cochrane Diagnostic Test Ac-
curacy (DTA) reviews on the diagnosis and staging of melanoma
and keratinocyte skin cancers conducted for the National Insti-
tute for Health Research (NIHR) Cochrane Systematic Reviews
Programme. Appendix 1 shows the content and structure of the
programme. Table 1 provides a glossary of terms used.
Target condition being diagnosed
There are three main forms of skin cancer. Melanoma has the
highest skin cancer mortality (Cancer Research UK 2017); how-
ever, the most common skin cancers in Caucasian populations are
those arising from keratinocyte cells: basal cell carcinoma (BCC)
and cutaneous squamous cell carcinoma (cSCC) (Gordon 2013;
Madan 2010). In 2003, theWorldHealthOrganization estimated
that between two and three million ’non-melanoma’ skin cancers
(of which BCC is estimated to account for around 80% and cSCC
for around 16% of cases) and 132,000 melanoma skin cancers
occur globally each year (WHO 2003).
In this DTA review, the target conditions of interest were:
melanoma, BCC, and cSCC. We also examined accuracy for the
target condition of any skin cancer or other lesion requiring exci-
sion, including melanoma or atypical intraepidermal melanocytic
variants, keratinocyte skin cancer, any other skin cancer, and
severely dysplastic melanocytic lesions.
Melanoma
Melanoma arises from uncontrolled proliferation of melanocytes
- the epidermal cells that produce pigment or melanin. Melanoma
can occur in any organ that contains melanocytes, including mu-
cosal surfaces, the back of the eye, and lining around the spinal
cord and brain, but most commonly arises in the skin. Cutaneous
melanoma refers to any skin lesion with malignant melanocytes
present in the dermis, and includes superficial spreading, nodu-
lar, acral lentiginous, and lentigo maligna melanoma variants (see
Figure 1) (SIGN 2017). Melanoma in situ refers to malignant
melanocytes that are contained within the epidermis and have not
yet invaded the dermis, but are at risk of progression to melanoma
if left untreated. Lentigo maligna, a subtype of melanoma-in-situ
in chronically sun-damaged skin, denotes another form of prolif-
eration of abnormal melanocytes. Melanoma in situ and lentigo
maligna are both atypical intraepidermal melanocytic variants. All
forms of melanoma in situ can progress to invasive melanoma if
its growth breaches the dermoepidermal junction (DEJ) during a
vertical growth phase, although malignant transformation is both
lower and slower for lentigo maligna than for melanoma in situ
(Kasprzak 2015).Melanoma is one of themost dangerous forms of
skin cancer, with the potential to metastasise to other parts of the
body via the lymphatic system and bloodstream. It accounts for
only a small percentage of skin cancer cases but is responsible for up
to 75% of skin cancer deaths (Boring 1994; Cancer Research UK
2017). The incidence of melanoma rose to over 200,000 newly
diagnosed cases worldwide in 2012 (Erdmann 2013; Ferlay 2015),
with an estimated 55,000 deaths (Ferlay 2015). The highest inci-
dence is observed in Australia with 13,134 new cases of melanoma
of the skin in 2014 (ACIM 2017) and in New Zealand with 2341
registered cases in 2010 (HPA andMelNetNZ 2014). For 2014 in
the USA, the predicted incidence was 73,870 per annum and the
predicted number of deaths was 9940 (Siegel 2015). The highest
rates in Europe are seen in north-western Europe and the Scandi-
navian countries, with a highest incidence reported in Switzerland:
25.8 per 100,000 in 2012. Rates in England have tripled from 4.6
and 6.0 per 100,000 in men and women, respectively, in 1990,
to 18.6 and 19.6 per 100,000 in 2012 (EUCAN 2012). In the
UK, melanoma has one of the fastest rising incidence rates of any
cancer, and has had the biggest projected increase in incidence be-
tween 2007 and 2030 (Mistry 2011). In the decade leading up to
2013, age-standardised incidence increased by 46%, with 14,500
new cases in 2013 and 2459 deaths in 2014 (Cancer Research UK
2017). Rates are higher in women than in men; however, the rate
of incidence in men is increasing faster than in women (Arnold
2014). The rising incidence in melanoma is thought to be primar-
ily related to an increase in recreational sun exposure and tanning
bed use and an increasingly ageing population with higher life-
time recreational ultraviolet (UV) exposure, in conjunction with
possible earlier detection (Belbasis 2016; Linos 2009). Putative
risk factors including eye and hair colour, skin type and density of
freckles, history of melanoma, sunburn, and presence of particular
lesion types are reviewed in detail elsewhere (Belbasis 2016).
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Figure 1. Sample photographs of superficial spreading melanoma (left) and nodular melanoma (right).
Copyright © 2010 Dr Rubeta Matin: reproduced with permission.
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A database of over 40,000 US patients from 1998 onwards which
assisted the development of the 8th American Joint Committee
on Cancer (AJCC) Staging System indicated a five-year survival of
97% to 99% for stage I melanoma, dropping to between 32% and
93% for stage III disease depending on tumour thickness, the pres-
ence of ulceration and number of involved nodes (Gershenwald
2017). While these are substantial increases relative to survival in
1975 (Cho 2014), increasing incidence between 1975 and 2010
means that mortality rates have reportedly remained static. This
observation, coupled with increasing incidence of localised dis-
ease, suggests that improvements in survival may be due to earlier
detection and heightened vigilance (Cho 2014). Targeted thera-
pies for stage IV melanoma (e.g. BRAF inhibitors) have improved
survival expectation and immunotherapies are evolving such that
long-term survival is being documented (Pasquali 2018).
Basal cell carcinoma
BCCcan arise frommultiple stem cell populations, including from
the follicular bulge and interfollicular epidermis (Grachtchouk
2011). Growth is usually localised, but it can infiltrate and dam-
age surrounding tissue, which if left untreated can cause consid-
erable destruction and disfigurement, particularly when located
on the face (Figure 2). The four main types of BCC are superfi-
cial, nodular, morphoeic, or infiltrative, and pigmented. Lesions
typically present as slow-growing asymptomatic papules, plaques,
or nodules which may bleed or form ulcers that do not heal
(Firnhaber 2012). People with BCC often present themselves to
healthcare professionals with a non-healing lesion rather than spe-
cific symptoms such as pain. Many lesions are diagnosed inciden-
tally (Gordon 2013).
Figure 2. Sample photographs of basal cell carcinoma (left) and cutaneous squamous cell carcinoma (right).
Copyright © 2012 Dr Rubeta Matin: reproduced with permission.
BCC most commonly occurs on sun-exposed areas of the head
and neck (McCormack 1997), and are more common in men
and in people over the age of 40 years. A rising incidence of
BCC in younger people has been attributed to increased recre-
ational sun exposure (Bath-Hextall 2007a; Gordon 2013; Musah
2013). Other risk factors include Fitzpatrick skin types I and II
(Fitzpatrick 1975; Lear 1997; Maia 1995); previous skin cancer
history; immunosuppression; arsenic exposure; and genetic predis-
position, such as in basal cell naevus (Gorlin’s) syndrome (Gorlin
2004; Zak-Prelich 2004). Annual incidence is increasing world-
wide; Europe has experienced a mean increase of 5.5% per year
since the late 1970s, the USA 2% per year, while estimates for the
UK show incidence appears to be increasing more steeply at a rate
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of an additional 6 per 100,000 persons per year (Lomas 2012).
The rising incidence has been attributed to an ageing population,
changes in the distribution of known risk factors, particularly UV
radiation, and improved detection due to the increased awareness
amongboth practitioners and the general population (Verkouteren
2017). Hoorens 2016 points to evidence for a gradual increase in
the size of BCCs over time, with delays in diagnosis ranging from
19 to 25 months.
According to National Institute for Health and Care Excellence
(NICE) guidance (NICE 2010), low-risk BCCs are nodular le-
sions occurring in people older than 24 years who are not im-
munosuppressed and do not have Gorlin’s syndrome. Further-
more, lesions should be located below the clavicle; should be small
(less than 1 cm) with clinically well-defined margins; not recur-
rent following incomplete excision or other treatment; and not
in awkward or highly visible locations (NICE 2010). Superficial
BCCs are also typically low risk and may be amenable to medical
treatments such as cryotherapy, photodynamic therapy (PDT), or
topical immunomodulatory therapy (e.g. 5% imiquimod cream)
(Kelleners-Smeets 2017). Assigning BCCs as low or high risk in-
fluences the management options (Batra 2002; Randle 1996).
Advanced locally destructive BCC can be found on the H-area of
the face (Lear 2014), can arise from long-standing untreated le-
sions, or from a recurrence of aggressive BCC after primary treat-
ment (Lear 2012). Very rarely, BCC may metastasise to regional
and distant sites resulting in death; this is particularly true for large
neglected lesions in people who are immunosuppressed, or people
with Gorlin’s syndrome (McCusker 2014). Rates of metastasis are
reported at 0.0028% to 0.55% with very poor survival rates (Lo
1991). It is recognised that basosquamous carcinoma (more like
a high risk cSCC in behaviour and not considered a true BCC) is
likely to have accounted for many cases of apparent metastases of
BCC, hence the spuriously high reported incidence in some stud-
ies of up to 0.55% which is not seen in clinical practice (Garcia
2009).
Squamous cell carcinoma of the skin
Primary cSCC arises from the keratinising cells of the epidermis
or its appendages. cSCC typically presents with an ulcer or firm
(indurated) papule, plaque, or nodule (Griffin 2016), often with
an adherent crust (Madan 2010) (Figure 2). cSCC can arise in the
absence of a precursor lesion, or may develop from pre-existing
actinic keratosis or Bowen’s disease (considered by some clinicians
to be cSCC in situ); the estimated annual risk of progression being
less than 1% to 20% for newly arising lesions (Alam 2001), and
5% for pre-existing lesions (Kao 1986). It remains locally invasive
for a variable length of time, but has the potential to spread to
the regional lymph nodes or via the bloodstream to distant sites,
especially in immunosuppressed people (Lansbury 2010). High-
risk lesions are those arising on the lip or ear, recurrent cSCC, le-
sions arising on non-exposed sites, within scars or chronic ulcers,
tumours more than 20 mm in diameter and tumours with a his-
tological depth of invasion exceeding 4 mm, and poor differentia-
tion status on pathological examination (Motley 2009). Perineural
nerve invasion (PNI) of at least 0.1 mm in diameter is a further
documented risk factor for high-risk cSCC (Carter 2013).
Chronic UV light exposure through recreation or occupation is
strongly linked to cSCC occurrence (Alam 2001). It is particularly
common inpeoplewith fair skin and in less common genetic disor-
ders of pigmentation, such as albinism, xeroderma pigmentosum,
and recessive dystrophic epidermolysis bullosa (RDEB) (Alam
2001). Other recognised risk factors include immunosuppres-
sion; chronic wounds; arsenic or radiation exposure; certain drug
treatments, such as voriconazole and BRAF mutation inhibitors;
and previous skin cancer history (Baldursson 1993; Chowdri
1996; Dabski 1986; Fasching 1989; Lister 1997; Maloney 1996;
O’Gorman 2014). In solid-organ transplant recipients, cSCC is
themost common formof skin cancer; the risk of developing cSCC
has been estimated at 65 to 253 times that of the general popula-
tion (Hartevelt 1990; Jensen 1999; Lansbury 2010). Overall, local
recurrence of cSCC at five years is estimated at 8% and metastatic
recurrence at 5%. The five-year survival rate of metastatic cSCC
of the head and neck is around 60% (Moeckelmann 2018).
Treatment
For primary melanoma, the mainstay of definitive treatment is
wide local excision of the lesion, to remove both the tumour and
any malignant cells that might have spread into the surround-
ing skin (Garbe 2016; Marsden 2010; NICE 2015a; SIGN 2017;
Sladden 2009). Recommended surgical margins vary according to
tumour thickness (Garbe 2016), and stage of disease at presenta-
tion (NICE 2015a). Following histological confirmation of diag-
nosis, the lesion is staged according to the AJCC Staging System
to guide treatment (Balch 2009). Stage 0 refers to melanoma in
situ; stages I to II indicate localised melanoma; stage III occurs
where there is regional metastasis; and stage IV indicates distant
metastasis (Balch 2009). The main prognostic indicators can be
divided into histological and clinical factors. Histologically, Bres-
low thickness is the single most important predictor of survival,
as it is a quantitative measure of tumour invasion which correlates
with the propensity for metastatic spread (Balch 2001). Micro-
scopic ulceration, mitotic rate, microscopic satellites, regression,
lymphovascular invasion, and nodular (rapidly growing) or ame-
lanotic (lacking in melanin pigment) subtypes are also associated
with worse prognosis (Moreau 2013; Shaikh 2012). Independent
of tumour thickness, prognosis is worse in: older people, males,
people with recurrent lesions, and in people with distant lymph
node involvement (micro or macroscopic) or metastatic disease
(or both) at the time of primary presentation. There is debate re-
garding the prognostic effect from primary lesion site, with some
evidence suggesting a worse prognosis for truncal lesions or those
on the scalp or neck (Zemelman 2014).
Treatment for BCC and cSCC can be different to melanoma,
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in that there is a range of primary treatment options that in-
clude surgery, other destructive techniques such as cryotherapy
or electrodesiccation, and topical chemotherapy. One Cochrane
systematic review of 27 randomised controlled trials (RCTs) of
interventions for BCC found very little good-quality evidence for
any of the interventions used (Bath-Hextall 2007b). Complete
surgical excision of primary BCC has a reported five-year recur-
rence rate of less than 2% (Griffiths 2005; Walker 2006), lead-
ing to significantly fewer recurrences than treatment with radio-
therapy (Bath-Hextall 2007b). After apparent clear histopatho-
logical margins (serial vertical sections) after standard excision
biopsy with 4 mm surgical peripheral margins taken there is a
five-year reported recurrence rate of around 4% (Drucker 2017).
Mohs micrographic surgery, whereby horizontal sections of the
excised specimen are microscopically examined intraoperatively,
and re-excision is undertaken until the margins are tumour-free,
can be considered for high-risk lesions such as on the centre of
the face where standard wider excision margins might lead to in-
complete excision or considerable functional or cosmetic impair-
ment, or both (Bath-Hextall 2007b; Lansbury 2010;Motley 2009;
Stratigos 2015). Bath-Hextall 2007b found a single trial compar-
ing Mohs micrographic surgery with a 3 mm surgical margin ex-
cision in BCC (Smeets 2004); the update of this study showed
non-significantly lower recurrence at 10 years with Mohs micro-
graphic surgery (4.4% compared to 12.2% after surgical excision,
P = 0.10) (van Loo 2014).
The main treatments for high-risk BCC are wide local excision,
Mohs micrographic surgery, and radiotherapy. For low-risk or su-
perficial subtypes of BCC, or for small or multiple (or both) BCCs
at low-risk sites (Marsden 2010), destructive techniques other than
excisional surgery may be used (e.g. electrodesiccation and curet-
tage or cryotherapy (Alam 2001; Bath-Hextall 2007b)). Alterna-
tively, non-surgical (or non-destructive) treatments may be con-
sidered (Bath-Hextall 2007b; Drew 2017; Kim 2014), including
topical chemotherapy such as imiquimod (Williams 2017), 5-flu-
orouracil (5-FU) (Arits 2013), ingenol mebutate (Nart 2015), and
photodynamic therapy (PDT) (Roozeboom 2016). Non-surgical
treatments are most frequently used for superficial forms of BCC,
with one head-to-head trial suggesting topical imiquimod was su-
perior to PDT and 5-FU (Jansen 2018). Although non-surgical
techniques are increasingly used, they do not allow histological
confirmation of tumour clearance, and their efficacy is dependent
on accurate characterisation of the histological subtype and depth
of tumour and so a baseline diagnostic biopsy can be helpful. The
2007 systematic review of BCC interventions found limited evi-
dence from very small RCTs for these approaches (Bath-Hextall
2007b), which have only partially been filled by subsequent studies
(Bath-Hextall 2014; Kim 2014; Roozeboom 2012). Most BCC
trials have compared interventionswithin the same treatment class,
and few have compared medical versus surgical treatments (Kim
2014).
One systematic review of interventions for primary cSCC found
only one RCT eligible for inclusion (Lansbury 2010). Therefore,
current practice relies on evidence from observational studies, as
reviewed in Lansbury 2013, for example. Surgical excision with
predetermined margins is usually the first-line treatment (Motley
2009; Stratigos 2015). Observational studies suggest low recur-
rence rates for small, low-risk lesions treated with cryotherapy or
curettage and electrodesiccation (recurrence rates less than 2%).
Estimates of recurrence afterMohsmicrosurgery, surgical excision,
or radiotherapy, which are likely to have been evaluated in higher-
risk populations, have shown pooled recurrence rates of 3%, 5.4%
and 6.4%, respectively, with overlapping confidence intervals; the
review authors advise caution when comparing results across treat-
ments (Lansbury 2013).
Index test(s)
Optical coherence tomography (OCT) is a non-invasive technol-
ogy that was first applied to the diagnosis of skin lesions in 1997
(Welzel 1997). The technique uses a hand-held probe based on the
same principle as ultrasound, but, instead of using sound waves,
it uses low-coherence interferometry to measure the optical scat-
tering of near-infrared (1310 nm) light waves from under the sur-
face of the skin; an image similar to a sonograph is created based
on multiple parallel scans (Hussain 2015; Olsen 2015) (Figure
3; Figure 4). Both two-dimensional (2D) and three-dimensional
(3D) images can be created. There are several different types of
OCT, the most commonly used in dermatological research is fre-
quency domain or swept sourceOCTwhere several scans are taken
using a rotating optical mirror to construct multi-slice scans; these
can create vertical cross-sectional slices of skin, or ’en-face’ im-
ages of horizontal layers (as with reflectance confocal microscopy
(RCM)).
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Figure 3. Swept-source optical coherence tomography scanner (Michelson Diagnostics VivoSight Rx).
Copyright © 2017 Guy’s & St Thomas’ Hospital Trust: reproduced with permission.
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Figure 4. Optical coherence tomography (OCT) image of a 7 mm basal cell carcinoma (BCC) on the cheek
showing several BCC cell nests (left hand star is above and to the left of a BCC nest) and the position of the 2
mmmargin as drawn with a reflective ink pen (right hand star). The ink pen gives the appearance of increased
reflectivity in the epidermis, and causes a fine vertical linear interference of the OCT signal of the skin, giving a
unique OCT signature. In this case, the interference is also seen to mask the OCT signal from the dermis
under the pen mark. Copyright © 2017 Guy’s & St Thomas’ Hospital Trust: reproduced with permission.
A challenge for any imaging device is the trade-off between high
resolution (clearer image) and depth of penetration of the layers
of the skin (Olsen 2015). Conventional OCT devices can achieve
penetration depths of up to 2 mm, with axial resolutions of up
to 7.5 µm and lateral resolutions of 5 µm (Hussain 2015; Olsen
2015). Skin features that can be visualised include the epidermis
(for which many cancers display an alteration in histology); the
DEJ; the upper or papillary dermis; the lower or reticular der-
mis; blood vessels travelling through the upper dermis; skin ap-
pendages, such as hair follicles and sebaceous glands; and the nail
unit and nail plate (DermNet New Zealand 2013). High-defini-
tionOCTcan achieve axial and lateral resolutions of 3 µm (thereby
allowing single cells to be visualised) at a depth of up to 0.57 mm
(Boone 2015a; Hussain 2015; Olsen 2015).
OCT is not routinely used in current practice (NICE 2015a).
It is considered of particular potential for the differentiation of
non-pigmented lesions as pigmented lesions demonstrate regular
scattering patterns that inhibit the differentiation of malignant
frombenign lesions (Gambichler 2015a;Olsen2015). Preliminary
work using high-definition (HD) OCT in melanocytic lesions
suggests that pagetoid cells, fusion of rete ridges, and junctional
or dermal nests with atypical cells, or both, are more prevalent in
melanomas compared to benign nevi (Gambichler 2015b). One
review suggested that eight characteristics associated with BCC
have been variously reported for conventional OCT including:
disruption of layering, hyporeflective rounded areas surrounded
by a hyper-reflective halo (’honeycomb’ structures), palisading at
margin, dilated vessels, well-circumscribed black/signal poor areas,
intact DEJ with underlying dark rounded areas, thinning of the
epidermis, and horizontal signal intense cords (Figure 5) (Hussain
2015). While there are no data to suggest that conventional OCT
can discriminate between BCC subtypes (Calin 2013; Hussain
2015), HD OCT has been advocated as a tool to do so; however,
results to date have been conflicting (Boone 2012; Gambichler
2014; Hussain 2015). Features thought to describe cSCC lesions
by conventional OCT include destruction of the epidermis and
thickened epidermal layer; however, these are also visualised in
actinic keratosis and so are not thought to be adequately discrim-
inating (Reggiani 2015). Features thought to be useful for iden-
tifying cSCC by HD OCT include disruption of the DEJ, disar-
ranged epidermal pattern in the absence of honeycomb structures
(Boone 2015a), and very bright irregularly broadened cell outlines
masking the nucleus, which are thought to represent atypical ker-
atinocytes (Reggiani 2015).
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Figure 5. Optical coherence tomography (OCT) image of a nodular basal cell carcinoma (BCC) showing a
basal nest centrally (star). The Dark halo appearance is due to a cleft region fully encompassing the nest and
the presence of peripheral palisading. Copyright © 2013 Michelson Diagnostics Ltd: reproduced with
permission.
Internationally, there are numerous companies producing differ-
ent commercially available OCT devices, across a range of medical
specialities; Gambichler 2015a lists nine different devices applied
in dermatology. Imaging can reportedly be undertaken by clini-
cians or technicians, taking around 30 seconds to scan a lesion,
with results immediately available for review and discussion with
patients. No information on the cost of OCT was identified.
Clinical pathway
The diagnosis of skin lesions occurs in primary, secondary, and
tertiary care settings by both generalist and specialist healthcare
providers. In the UK, people with concerns about a new or chang-
ing lesion will either present to their general practitioner (GP) or
directly to a specialist in secondary care, which could include a der-
matologist, plastic surgeon, general surgeon, other specialist sur-
geon (such as an ear, nose, and throat (ENT) specialist or maxillo-
facial surgeon), or ophthalmologist (Figure 6). Current UK guide-
lines recommend that all suspicious pigmented lesions presenting
in primary care should be assessed by taking a clinical history and
visual inspection using the revised seven-point checklist (MacKie
1990); lesions suspected to be melanoma (Chao 2013; Marsden
2010; NICE 2015b) or cSCC (London Cancer Alliance 2013)
should be referred for appropriate specialist assessment within two
weeks. Generalist care providers increasingly carry out manage-
ment of low-risk BCC (CCAAC Network 2008).
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Figure 6. Current clinical pathway for people with skin lesions.
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The specialist clinician will use history-taking, visual inspection
of the lesion (in comparison with other lesions on the skin), and
usually dermoscopy to inform a clinical decision. If melanoma or
cSCC is suspected, then urgent excision is recommended. Lesions
such as BCC may be referred for a diagnostic biopsy, followed by
appropriate treatment or further surveillance or reassurance and
discharge.
Prior test(s)
Fundamental to the diagnosis of skin cancer is history-taking and
clinical examination. In the UK, this is typically done at two de-
cision points - first in the GP surgery where a decision is made to
refer or not to refer, and then a second time by a dermatologist
or other professional in secondary care where a decision is made
to biopsy or not. However, a range of technologies have emerged
to aid diagnosis to reduce the number of biopsies. Dermoscopy in
particular has become the most widely used tool for clinicians to
try to obtain an accurate assessment of melanoma following visual
inspection (Argenziano 1998; Argenziano 2012; Haenssle 2010;
Kittler 2002), although is less well established for BCC or cSCC
diagnosis (Dinnes 2018a).
Visual inspection of the skin is undertaken iteratively, using both
implicit pattern recognition (non-analytical reasoning) and more
explicit ’rules’ based on conscious analytical reasoning (Norman
2009), the balance of which will vary according to experience and
familiarity with the diagnostic question. Various attempts have
been made to formalise the ’mental rules’ involved in analytical
pattern recognition for melanoma, ranging from a setting out of
lesion characteristics that should be considered (Friedman 1985;
Sober 1979), to formal scoring systems with explicit numerical
thresholds. The revised seven-point checklist, for example, assesses
change in lesion size, shape, colour, inflammation, crusting or
bleeding, sensory change, or diameter 7 mm or greater (MacKie
1990).Other available tools include the ABCD(E) approach (pres-
ence of features: asymmetry, border, colour, diameter, evolution)
(Friedman 1985; Thomas 1998), and ’ugly duckling’ sign (Grob
1998). For keratinocyte skin cancers, visual inspection relies pri-
marily on pattern recognition and accuracy has been shown to vary
according to the expertise of the clinician. Primary care physicians
have been found to miss over half of BCC (Offidani 2002), and
to inappropriately diagnose one third of BCC (Gerbert 2000). In
contrast, one Australian study found that trained dermatologists
were able to detect 98% of BCC, but with a specificity of only
45% (Green 1988).
Dermoscopy is a non-invasive, in vivo technique that uses a hand-
held microscope and incident light (with or without oil immer-
sion) to reveal subsurface images of the skin at increasedmagnifica-
tion of ×10 to×100 (Kittler 2011). Althoughwidely used, the accu-
racy of dermoscopy largely depends on the experience and training
of the examiner (Binder 1997; Kittler 2002; Kittler 2011). Pattern
analysis (Pehamberger 1987; Steiner 1987) is thought to be the
most specific and reliable technique to aid dermoscopy interpreta-
tion when used by specialists (Maley 2014); however, dermoscopic
histological correlations have been established and diagnostic algo-
rithmshave beendeveloped to improvemelanomadiagnosis, using
features based on colour, aspect, pigmentation pattern, and skin
vessels, including the ABCD rule for dermoscopy (Nachbar 1994;
Stolz 1994), the Menzies approach (Menzies 1996), the seven-
point dermoscopy checklist (Annessi 2007; Argenziano 1998;
Argenziano 2001; Gereli 2010), and the three-point checklist
(Gereli 2010). Similar algorithms have been developed to aid in
the detection of BCC (Menzies 2000; Navarrete-Dechent 2016).
The accuracy, and comparative accuracy, of visual inspection and
dermoscopy and their associated scoring systems for the detection
of both melanoma and keratinocyte skin cancers is summarised in
three reviews in this series (Dinnes 2018a; Dinnes 2018b; Dinnes
2018c).
Role of index test(s)
Used in conjunction with clinical or dermoscopic suspicion of
malignancy, or both, OCT may provide a means of reducing the
number of false-positive diagnoses and, therefore, reduce unnec-
essary biopsies in suspected BCC (Gambichler 2015a; Hussain
2015; Reggiani 2015). OCT is considered to lie within the ’imag-
ing gap’ between HR ultrasound and RCM in terms of depth of
penetrationof the skin and resolutionof the resulting image (Olsen
2015; Themstrup 2015). OCT has a lower depth of penetration
but higher resolution in comparison to ultrasound. Compared to
RCM, OCT uses a longer wavelength (830 nm as opposed to
1305 nm for OCT), has considerably deeper penetration (RCM
less than 300 µm; OCT less than 2 mm) meaning it can visualise
deeper into the dermis, has a greater depth of focus (RCM 3µm to
5 µm; OCT 1 mm), and wider basic field of view (RCM basic 500
× 500 µm in the horizontal plane; OCT basic 6 × 6 mm). How-
ever, OCT has lower lateral resolution in comparison to RCM
(RCM1µm, cellular;OCT7.5 µm, near cellular), although newer
HD OCT reportedly has the capacity to visualise most RCM fea-
tures (Olsen 2015). Both OCT and RCM have fields of view that
are extendible by mechanical scanning and image mosaicking, al-
though for equivalent fields of view 3D imaging is much faster
with OCT (RCM for mosaicked field of view and stack greater
than 10 minutes; OCT six cross-sectional frames per second, less
than 2 minutes for 6 × 6 × 2 mm volume). Therefore, OCT may
be well placed to provide a combination of diagnostic informa-
tion that cannot be retrieved with either confocal microscopy or
ultrasound alone. Furthermore, the speed of OCT imaging al-
lows rapid assessment of multiple lesions potentially obviating the
need for multiple biopsies. In addition to diagnosis, OCT has
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the potential to inform therapeutic decisions for people with a
diagnosis of BCC, by determining the thickness of lesions, and
when using HD OCT potentially also establishing the subtype of
BCC. Once diagnosed, superficial BCC can be treated using non-
surgical treatments (listed in Target condition being diagnosed),
which could be advantageous for multiple lesions or lesions arising
on cosmetically critical sites (e.g. face) (Powell 2000). Excisional
surgery and Mohs micrographic surgery are the most successful
treatments for nodular/infiltrative BCC, although smaller nodular
BCCs in low-risk areas can also be treated with topical treatments
(Williams 2017). Therefore, the ability to confirm the subtype of
BCC in these patients using a fast and non-invasive approach is
attractive since it could reduce treatment-related morbidity, and
possibly reduce the cost of management.
The potential role of OCT to diagnose melanomas is less clear,
given that its resolution is insufficient to visualise melanocytes, a
key feature for the diagnosis of melanoma. However, OCT has
been suggested to allow the identification of architectural charac-
teristics that are useful for differentiating malignant from benign
melanocytic lesions (Gambichler 2007). Although the primary
aim in diagnosing potentially life-threatening conditions such as
melanoma is to minimise false-negative diagnoses (to avoid delay
to diagnosis and even death), a test that can reduce false-positive
clinical diagnoses without missing true cases of disease has patient
and resource benefits. False-positive clinical diagnoses not only
cause unnecessary morbidity from the biopsy, but also increase
patient anxiety. Pigmented lesions are common, so the resource
implication for even a slight increase in the threshold to excise
lesions in populations where melanoma rates are increasing, will
avoid a considerable healthcare burden to both patient and health-
care provider, as long as such lesions turn out to be harmless.
A delay in the diagnosis of BCC as a result of a false-negative test
is usually not as serious as for melanoma because BCC is usually
slow-growing and very unlikely to metastasise. However, delayed
diagnosis can result in a larger and more complex excision. Very
sensitive tests for BCC, which compromise on lower specificity
leading to a high false-positive rate, are likely to result in an enor-
mous burden of skin surgery because BCC is so common, which
the National Health Service (NHS) will struggle to cope with, so
a balance between sensitivity and specificity is needed. With the
greater potential for cSCC tometastasise, delayed diagnosis can be
a much more serious problem, ultimately impacting on long-term
prognosis. A test that can accurately distinguish between BCC,
cSCC, and melanoma could reduce the time to diagnosis, better
inform appropriate treatment decisions in people who need it, and
could avoid unnecessary surgical procedures.
OCT has also been investigated for its ability to identify lesion
thickness, define tumour margins, and to assist in Mohs surgery,
reducing the number of layers needed to remove the lesion (De
Carvalho 2018; Gambichler 2015a; Hussain 2015; Olsen 2015);
however, these applications are not considered in this review.
Alternative test(s)
Several other non-invasive diagnostic technologies that are not
routinely used in practice may also have a role for the diagno-
sis of skin cancer in a specialist setting, and these are being re-
viewed as part of our series of Cochrane DTA reviews on the di-
agnosis of melanoma and keratinocyte cancers: visual inspection
and dermoscopy (Dinnes 2018a; Dinnes 2018b; Dinnes 2018c),
RCM (Dinnes 2018d; Dinnes 2018e), high-frequency ultrasound
(HFUS) (Dinnes 2018f), and computer-assisted diagnosis (CAD)
techniques that make use of dermoscopic or spectroscopic images,
or other spectroscopic data (Ferrante di Ruffano 2018a).
RCM in particular is emerging as a potential alternative or adjunct
to dermoscopy for the diagnosis of skin cancer (Edwards 2016),
and can be used to visualise horizontally sectioned images of the
skin at a cellular lateral resolution of about 1 µm, in vivo to the
depth of the upper dermis. The contrast for the monochrome im-
ages produced is achieved by the variation of the optical properties
within the skin when illuminated by a near-infrared light (830
nm); the greatest contrast is achieved from melanin, so that RCM
is advocated as being particularly useful for assessing pigmented
lesions (Dinnes 2018e).
CAD or artificial intelligence-based techniques analyse either der-
moscopic or spectroscopic images, or other forms of spectroscopic
data (such as diffuse reflectance or electrical impedance measure-
ments), using predefined algorithms to process and manipulate
acquired images to identify the features that discriminate malig-
nant from benign lesions (Esteva 2017; Rajpara 2009). A vari-
ety of spectroscopy-based tests have been developed and evalu-
ated in both primary and secondary care settings, including SIAs-
copy (Moncrieff 2002;Walter 2012), MelaFind (Hauschild 2014;
Monheit 2011; Wells 2012), and Nevisense (Malvehy 2014). Ul-
trasound relies on themeasurement of soundwave reflections from
the tissues of the body. At lower frequencies, the deeper structures
of the body such as the internal organs can be visualised, while
HFUS with transducer frequencies of at least 20 MHz has a much
lower depth of tissue penetration but produces a higher resolution
image of tissues and structures closer to the skin surface. Therefore,
HFUS may offer additional diagnostic information compared to
other technologies; however, evidence to date is scarce and of gen-
erally poor quality (Dinnes 2018f).
Evidence permitting, the accuracy of available tests will be com-
pared in an overview review, exploiting within-study comparisons
of tests and allowing the analysis and comparison of commonly
used diagnostic strategies where tests may be used singly or in
combination.
Alternative tests identified as potential candidates for review but
for which no eligible studies were found include volatile or-
ganic compounds (including canine odour detection) (Abaffy
2010; Church 2001; D’Amico 2008; Gallagher 2008; Kwak
2013; Williams 1989), and gene expression analysis (Ferris 2012;
Wachsman 2011).
We also considered and excluded anumber of tests from this review
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including tests used in the context of monitoring people, such as
total body photography of people with large numbers of typical
or atypical naevi, and histopathological confirmation following
lesion excision. Histopathological confirmation is the established
reference standard for melanoma diagnosis and will be one of
the standards against which the index tests are evaluated in these
reviews.
Rationale
Our series of reviews of diagnostic tests used to assist the clinical
diagnosis of melanoma, and of the keratinocyte skin cancers BCC
and cSCC, aims to identify the most accurate approaches to di-
agnosis and provide clinical and policy decision-makers with the
highest possible standard of evidence on which to base decisions.
With increasing rates ofmelanoma incidence and the push towards
the use of dermoscopy and other HR image analysis in primary
care, the anxiety around missing early cases needs to be balanced
to avoid referring too many people with benign lesions for a spe-
cialist opinion. For keratinocyte skin cancers, the increasing avail-
ability of a wider range of tests means these technologies must be
evaluated for their ability to differentiate and appropriately triage
keratinocyte skin cancers, to avoid sending too many people with
benign or low-risk lesions for a specialist opinion and possible ex-
cision or biopsy, while not missing those people who have lesions
that require treatment. It is questionable whether all skin cancers
picked up by sophisticated techniques, even in specialist settings,
help to reduce morbidity and mortality or whether newer tech-
nologies run the risk of increasing false-positive diagnoses. It is
also possible that use of some technologies (e.g. widespread use of
dermoscopy in primary care with no training) could actually result
in harm by missing skin cancers if they are used as replacement
technologies for traditional history-taking and clinical examina-
tion of the entire skin. Many branches of medicine have noted the
danger of such ’gizmo idolatry’ among doctors (Leff 2008).
Despite having been first applied to skin lesions in the 1990s,
OCT - and particularly HD OCT - is a fast developing novel
technology, that if sufficiently accurate could have considerable
potential to assist in the non-invasive diagnosis of skin cancers.
Existing systematic reviews of OCT focus on the important ques-
tion of synthesising the histological and imaging correlates of skin
cancer diagnoses; however, this emphasismeans their selection and
presentation of test accuracy evidence is not as rigorous and com-
prehensive as would be expected in systematic reviews of DTA.
In addition, none reported undertaking any assessment of quality
assessment or attempted meta-analysis (Calin 2013; Gambichler
2015a;Hussain 2015;Olsen 2015), and all were limited by out-of-
date searches (themost recent finishing inMay 2015,Olsen 2015).
In this rapidly advancing field, there is a need for an up-to-date
analysis of the accuracy of OCT for the diagnosis of melanoma
and keratinocyte skin cancer.
This review follows a generic protocol which covers the full series
of Cochrane DTA reviews for the diagnosis of melanoma (Dinnes
2015a), and for the diagnosis of keratinocyte skin cancers (Dinnes
2015b). The Background and Methods sections of this review
therefore use some text that was originally published in the proto-
col (Dinnes 2015a; Dinnes 2015b), and text that overlaps some of
our other reviews (Dinnes 2018d; Dinnes 2018e; Dinnes 2018f;
Ferrante di Ruffano 2018a; Ferrante di Ruffano 2018b).
O B J E C T I V E S
To determine the diagnostic accuracy of OCT for the detec-
tion of cutaneous invasive melanoma and atypical intraepidermal
melanocytic variants, basal cell carcinoma (BCC), or cutaneous
squamous cell carcinoma (cSCC) in adults.
Secondary objectives
To determine the diagnostic accuracy of OCT in comparison to
standard diagnostic practice for the detection of either cutaneous
invasive melanoma and atypical intraepidermal melanocytic vari-
ants, BCC, or cSCC in adults.
To determine the diagnostic accuracy of OCT for the detection
of invasive melanoma alone.
Investigation of sources of heterogeneity
We set out to address a range of potential sources of heterogeneity
for investigation across our series of reviews, as outlined in our
generic protocol (Dinnes 2015a; Dinnes 2015b); however, our
ability to investigate these and other sources of heterogeneity was
necessarily limited by the data available for each reviewed test.
1. Population characteristics
• General versus higher-risk populations.
• Participant population: primary/secondary/specialist unit.
• Lesion type: any pigmented; melanocytic.
• Inclusion of multiple lesions per participant.
• Ethnicity.
2. Index test characteristics
• In-person versus remote image-based test interpretations.
• Nature and definition of criteria for test positivity.
• Observer experience with the index test.
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3. Reference standard characteristics
• Reference standard used.
• Whether histology-reporting met pathology-reporting
guidelines.
• Use of excisional versus diagnostic biopsy.
• Whether two independent dermatopathologists reviewed
histological diagnosis.
4. Study quality
• Consecutive or random sample of participants recruited.
• Index test interpreted blinded to the reference standard
result.
• Index test interpreted blinded to the result of any other
index test.
• Presence of partial or differential verification bias (whereby
only a sample of those subject to the index test were verified by
the reference test or by the same reference test with selection
dependent on the index test result).
• Use of an adequate reference standard.
• Overall risk of bias.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included test accuracy studies that allow comparison of the
result of the index test with that of a reference standard, including
the following:
• studies where all participants received a single index test
and a reference standard;
• studies where all participants received more than one index
test(s) and reference standard;
• studies where participants were allocated (by any method)
to receive different index tests or combinations of index tests and
all received a reference standard (between-person comparative
(BPC) studies);
• studies that recruited series of participants unselected by
true disease status (referred to as case series for the purposes of
this review);
• diagnostic case-control studies that separately recruited
diseased and non-diseased groups (see Rutjes 2005); however, we
did not include studies that compared results for malignant
lesions to those for healthy skin (i.e. with no lesion present);
• both prospective and retrospective studies; and
• studies that retrieved and prospectively interpreted
previously acquired clinical or dermoscopic images for study
purposes.
We excluded studies from which we could not extract 2×2 con-
tingency data or if they included fewer than five disease-positive
or five disease-negative cases. The size threshold of five was arbi-
trary. However, such small studies are unlikely to add precision to
estimate of accuracy.
Studies available only as conference abstracts were excluded; how-
ever, attempts were made to identify full papers for potentially
relevant conference abstracts (Searching other resources).
Participants
We included studies in adults with pigmented skin lesions or le-
sions suspicious for melanoma, BCC, or cSCC.
We excluded studies that recruited only participants with malig-
nant diagnoses. We excluded studies with more than 50% of par-
ticipants aged 16 years and under.
Index tests
We included studies evaluating OCT alone, or OCT in compar-
ison to visual inspection or dermoscopy, or both. We included
all established algorithms or checklists to assist diagnosis. We in-
cluded studies developing new algorithms or methods of diagnosis
(i.e. derivation studies), if they:
• used a separate independent ’test set’ of participants or
images to evaluate the new approach; or
• investigated lesion characteristics that had previously been
suggested as associated with melanoma, BCC, or cSCC and the
study reported accuracy based on the presence or absence of
specific combinations of characteristics.
We excluded studies if they:
• used a statistical model to produce a data-driven equation,
or algorithm based on multiple diagnostic features, with no
separate test set;
• used cross-validation approaches such as ’leave-one-out’
cross-validation (Efron 1983);
• evaluated the accuracy of the presence or absence of
individual OCT characteristics or morphological features, with
no overall diagnosis of malignancy.
There were no exclusions made according to test observer.
Target conditions
The target conditions were defined as the detection of:
• any form of invasive cutaneous melanoma or atypical
intraepidermal melanocytic variants (i.e. including melanoma in
situ, or lentigo maligna, which had a risk of progression to
invasive melanoma);
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• BCC (all types);
• Invasive cSCC (we did not consider cutaneous SCC in situ,
such as Bowen’s disease, as disease-positive); and
• any skin cancer or other lesion requiring excision (including
melanoma or atypical intraepidermal melanocytic variants,
severely dysplastic melanocytic lesions, keratinocyte skin cancer,
and any other skin cancer).
Reference standards
The ideal reference standard was histopathological diagnosis of
the excised lesion or biopsy sample in all eligible lesions. A
qualified pathologist or dermatopathologist should have perform
histopathology. Ideally, reporting should be standardised detail-
ing a minimum dataset to include the histopathological features
of melanoma to determine the AJCC Staging System (e.g. Slater
2014). We did not apply the reporting standard as a necessary
inclusion criterion, but extracted any pertinent information.
Partial verification (applying the reference test only to a subset of
those undergoing the index test) was of concern given that lesion
excision or biopsy is unlikely to be carried out for all benign-ap-
pearing lesions within a representative population sample. There-
fore, we accepted clinical follow-up of benign-appearing lesions as
an eligible reference standard, while recognising the risk of differ-
ential verification bias (as misclassification rates of histopathology
and follow-up will differ) in our quality assessment of studies.
Additional eligible reference standards included cancer registry
follow-up and ’expert opinion’ with no histology or clinical fol-
low-up. Cancer registry follow-up is considered less desirable than
active clinical follow-up, as follow-up is not carried out within
the control of the study investigators. Furthermore, if participant-
based analyses as opposed to lesion-based analyses are presented,
it may be difficult to determine whether the detection of a ma-
lignant lesion during follow-up is the same lesion that originally
tested negative on the index test.
We considered all of the above eligible reference standards with
the following caveats:
• all study participants with a final diagnosis of the target
disorder must have had a histological diagnosis, either
subsequent to the application of the index test or after a period
of clinical follow-up, and
• at least 50% of all participants with benign lesions must
have had either a histological diagnosis or clinical follow-up to
confirm benignity.
Search methods for identification of studies
Electronic searches
The Information Specialist (SB) carried out a comprehensive
search for published and unpublished studies. A single large liter-
ature search was conducted to cover all topics in the programme
grant (see Appendix 1 for a summary of reviews included in the
programme grant). This allowed for the screening of search results
for potentially relevant papers for all reviews at the same time.
A search combining disease related terms with terms related to
the test names, using both text words and subject headings was
formulated. The search strategy was designed to capture studies
evaluating tests for the diagnosis or staging of skin cancer. As the
majority of records were related to the searches for tests for stag-
ing of disease, a filter using terms related to cancer staging and
to accuracy indices was applied to the staging test search, to try
to eliminate irrelevant studies, for example, those using imaging
tests to assess treatment effectiveness. A sample of 300 records that
would be missed by applying this filter was screened and the filter
adjusted to include potentially relevant studies. When piloted on
MEDLINE, inclusion of the filter for the staging tests reduced the
overall numbers by around 6000. The final search strategy, incor-
porating the filter, was subsequently applied to all bibliographic
databases as listed below (Appendix 2). The final search result was
cross-checked against the list of studies included in five systematic
reviews; our search identified all but one of the studies, and this
study was not indexed on MEDLINE. The Information Special-
ist devised the search strategy, with input from the Information
Specialist from Cochrane Skin. No additional limits were used.
We searched the following bibliographic databases to 29 August
2016 for relevant published studies:
• MEDLINE via Ovid (from 1946);
• MEDLINE In-Process & Other Non-Indexed Citations via
Ovid; and
• Embase via Ovid (from 1980).
We searched the following bibliographic databases to 30 August
2016 for relevant published studies:
• the Cochrane Central Register of Controlled Trials
(CENTRAL) 2016, Issue 7, in the Cochrane Library;
• the Cochrane Database of Systematic Reviews (CDSR)
2016, Issue 8, in the Cochrane Library;
• Cochrane Database of Abstracts of Reviews of Effects
(DARE) 2015, Issue 2;
• CRD HTA (Health Technology Assessment) database
2016, Issue 3; and
• CINAHL (Cumulative Index to Nursing and Allied Health
Literature via EBSCO from 1960).
We searched the followingdatabases for relevant unpublished stud-
ies using a strategy based on the MEDLINE search:
• CPCI (Conference Proceedings Citation Index), via Web of
Science™ (from 1990; searched 28 August 2016); and
• SCI Science Citation Index Expanded™ via Web of
Science™ (from 1900, using the ’Proceedings and Meetings
Abstracts’ Limit function; searched 29 August 2016).
We searched the following trials registers using the search terms
’melanoma’, ’squamous cell’, ’basal cell’ and ’skin cancer’ combined
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with ’diagnosis’:
• Zetoc (from 1993; searched 28 August 2016).
• The US National Institutes of Health Ongoing Trials
Register (www.clinicaltrials.gov); searched 29 August 2016.
• NIHR Clinical Research Network Portfolio Database (
www.nihr.ac.uk/research-and-impact/nihr-clinical-research-
network-portfolio/); searched 29 August 2016.
• The World Health Organization International Clinical
Trials Registry Platform ( apps.who.int/trialsearch/); searched 29
August 2016.
We aimed to identify all relevant studies regardless of language
or publication status (published, unpublished, in press, or in
progress). We applied no date limits.
Searching other resources
We screened relevant systematic reviews identified by the searches
for their included primary studies, and included anymissed by our
searches.We checked the reference lists of all included papers, and
subject experts within the author team reviewed the final list of
included studies. We conducted no electronic citation searching.
Data collection and analysis
Selection of studies
At least one review author (JDorNC) screened titles and abstracts,
with any queries discussed and resolved by consensus. A pilot
screen of 539MEDLINE references showed good agreement (89%
with a kappa of 0.77) between screeners. We included primary
test accuracy studies and test accuracy reviews (for scanning of
reference lists) of any test used to investigate suspected melanoma,
BCC, or cSCC at initial screening. Both a clinical reviewer (from
one of a team of 12 clinician reviewers) and a methodologist re-
viewer (JD or NC) independently applied the inclusion criteria
independently to all full-text articles (Appendix 3); we resolved
disagreements by consensus or by a third party (JJD, CD, HW,
and RM). We contacted authors of eligible studies when studies
presented insufficient data to allow for the construction of 2×2
contingency tables.
Data extraction and management
One clinical (as detailed above) and one methodologist reviewer
(JD,NC, or LFR) independently extracted data concerning details
of the study design; participants; index test(s) or test combinations;
and criteria for index test positivity, reference standards, and data
required to complete a 2×2 diagnostic contingency table for each
index test using a piloted data extraction form. We extracted data
at all available index test thresholds. We resolved disagreements
by consensus or by a third party (JJD, CD, HW, and RM). We
entered data into Review Manager 5 (Review Manager 2014).
We contacted authors of included studies where information re-
lated to the target condition (in particular to allow the differentia-
tion of invasive cSCC from ’in situ’variants) or diagnostic thresh-
old were missing. We contacted authors of conference abstracts
published from 2013 to 2015 to ask whether full data were avail-
able. If we identified no full paper, wemarked conference abstracts
as ’pending’ and will revisit them in a future review update.
Dealing with multiple publications and companion papers
Where we identified multiple reports of a primary study, we max-
imised yield of information by collating all available data. Where
there were inconsistencies in reporting or overlapping study pop-
ulations, we contacted study authors for clarification in the first
instance. If this contact with authors was unsuccessful, we used
the most complete and up-to-date data source where possible.
Assessment of methodological quality
We assessed risk of bias and applicability of included studies using
the QUADAS-2 checklist (Whiting 2011), tailored to the review
topic (see Appendix 4 for full details of items, responses, and sum-
mary judgement criteria). We piloted the modified QUADAS-2
tool on a small number of included full-text articles. One clinical
(as detailed above) and one methodologist reviewer (JD, NC, or
LFR) independently assessed quality for the remaining studies; we
resolved any disagreement by consensus or by a third party where
necessary (JJD, CD, HW, and RM).
Statistical analysis and data synthesis
Due to paucity of data and differences in thresholds used to define
test positivity, we undertook no meta-analysis for the diagnosis
of melanoma or cSCC. We undertook statistical pooling for the
diagnosis of BCC.
For the diagnosis of cSCC at each threshold, any other skin cancers
(i.e. BCC) thatwere included in the study and thatwere incorrectly
identified as cSCCs (i.e. positive on OCT) were considered as
true-negative test results rather than as false positives, on the basis
that excision of such lesions may still have been appropriate for
the participants concerned. However, for the diagnosis of BCC,
any other skin cancers (e.g. melanomas or cSCCs) in the ’disease-
negative’ group that were incorrectly identified by OCT as BCCs
were kept as false-positive results. This decision was taken on the
basis that the clinical management of a lesion considered to be
a BCC (e.g. initiation of Mohs micrographic surgery, destructive
techniques or non-surgical treatments) could be quite different
to that for a melanoma or cSCC and could potentially lead to a
negative outcome for those concerned.
We plotted estimates of sensitivity and specificity on coupled forest
plots for each threshold under consideration. Our unit of analysis
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was the lesion rather than the person. This is because in skin can-
cer, initial treatment is directed to the lesion rather than systemi-
cally (thus it is important to be able to correctly identify cancerous
lesions for each person), and it is the most common way in which
the primary studies reported data. Although there is a theoretical
possibility of correlations of test errors when the same people con-
tribute data for multiple lesions, most studies included very few
people with multiple lesions and any potential impact on findings
was likely to be very small, particularly in comparison with other
concerns regarding risk of bias and applicability. For each analysis,
we included only one dataset per study to avoid multiple counting
of lesions.
To allow statistical pooling where multiple thresholds per algo-
rithm were reported (Wahrlich 2015), we analysed data separately
using each threshold. For tests where commonly used thresholds
were reported, we estimated summary operating points (summary
sensitivities and specificities) with 95% confidence intervals (CI)
and prediction regions using the bivariate hierarchical model (Chu
2006;Reitsma2005).Where inadequate datawere available for the
model to converge, we simplified themodel by assuming no corre-
lation between estimates of sensitivity and specificity (Takwoingi
2017).
We included data on the accuracy of visual inspection or der-
moscopy (or both) to allow comparisons of tests, but only if re-
ported in the included studies of OCT due to the known sub-
stantial unexplained heterogeneity in all studies of the accuracy
of dermoscopy (Dinnes 2018b). We extended the bivariate model
by addition of covariates to allow for differences in sensitivity and
specificity between OCT and visual inspection or dermoscopy (or
both), with the significance of differences being assessed using a
single likelihood ratio test comparing models with and without
the covariates.
Investigations of heterogeneity
We examined heterogeneity between studies by visually inspecting
the forest plots of sensitivity and specificity. There were insuffi-
cient numbers of studies to allow meta-regression to investigate
potential sources of heterogeneity.
Sensitivity analyses
We performed no sensitivity analyses.
Assessment of reporting bias
Because of uncertainty about the determinants of publication bias
for diagnostic accuracy studies and the inadequacy of tests for
detecting funnel plot asymmetry (Deeks 2005), we performed no
tests to detect publication bias.
R E S U L T S
Results of the search
The search identified andwe screened34,517unique references for
inclusion.Of these, we reviewed1051 full-text papers for eligibility
for any one of the suite of reviews of tests to assist in the diagnosis
of melanoma or keratinocyte skin cancer. Figure 7 documents a
PRISMA flow diagram of the search and eligibility results. Of the
1051 studies assessed, exclusions were due to lack of test accuracy
data (184 studies), or because they were derivation studies (141
studies), evaluated an ineligible index test (126 studies), included
ineligible populations (83 studies), assessed an ineligible target
condition (78 studies), had fewer than five malignant cases (72
studies), or did not meet our requirements for eligible reference
standards (i.e. at least 50% of all participants with benign lesions
had to have either a histological diagnosis or clinical follow-up to
determine the final diagnosis (76 studies)). A total of 43 studies
were potentially eligible for this review; ultimately five publications
(reporting five studies) were included. A list of the 38 studies
excluded from this review with reasons for exclusion is provided in
theCharacteristics of excluded studies table, with a list of all studies
excluded from the full series of reviews available as a separate pdf
(please contact skin.cochrane.org for a copy of the pdf ).
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Figure 7. PRISMA flow diagram.
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Across all skin cancer DTA reviews, Cochrane review authors con-
tacted the corresponding authors of 86 studies and asked them to
supply further information to allow study inclusion (37 studies),
to clarify diagnostic thresholds (18 studies), or target condition
definition (30 studies).
Characteristics of included studies
This review reported on five cohorts of participants with lesions
suspected of skin cancer, published in five study publications, and
providing nine datasets for OCT, two for visual inspection, and
two for dermoscopy. A description of thresholds used for diagnosis
across the studies is provided in Table 2 and summary study details
are presented in Appendix 5.
The five included studies consisted of four prospective case se-
ries and one study in which the design was unclear (Wahrlich
2015). Three were conducted in Germany (Gambichler 2015c;
Ulrich 2015; Wahrlich 2015), one in the Netherlands (Wessels
2015), and one in the US (Markowitz 2015). OCT manufactur-
ers funded three studies (Gambichler 2015c; Markowitz 2015;
Ulrich 2015); in Wahrlich 2015, the manufacturer provided the
OCT device, and Wessels 2015 did not report company funding.
Two studies were in participants with pigmented (Wessels 2015)
or melanocytic lesions (Gambichler 2015c) and focused on iden-
tification of melanomas. The remaining three studies examined
a series of non-pigmented lesions (Markowitz 2015 focused on
head and neck lesions), two focusing on ’pink’ lesions suspected of
being BCCs (Markowitz 2015; Ulrich 2015), and the third select-
ing non-pigmented lesions according to their histological diagno-
sis (Wahrlich 2015). All five studies analysed lesions selected for
excision or biopsy, two of which focused on clinically challenging
lesions (Markowitz 2015; Ulrich 2015). The studies also varied in
the degree of testing performed prior to study inclusion and per-
formance of the OCT scan: the two melanoma studies included
participants with clinical suspicion of melanoma and either prior
dermoscopy in all (Gambichler 2015c), or some (Wessels 2015),
study participants. All three studies of non-pigmented lesions re-
ported visual inspection as a prior test, with the case-control study
also reporting dermoscopy and histology (Wahrlich 2015), while
the two prospective studies performed dermoscopy and histology
during the study (Markowitz 2015; Ulrich 2015).
The five studies included 402 participants with 529 lesions, with
the numbers included in each study ranging from 33 to 164 par-
ticipants and 40 to 256 lesions. The prevalence of disease was
23% (Wessels 2015) and 27% (Gambichler 2015c) in the two
melanoma studies (both of which included only benign nevi in
the disease-negative group), and disease prevalence ranged from
58% (Wahrlich 2015) to 61% (Markowitz 2015) in the studies of
BCC. Of the three BCC studies, one did not describe diagnoses in
the disease-negative group (Markowitz 2015); one included par-
ticipants with cSCC, Bowen’s disease, and actinic keratosis only
(Wahrlich 2015); while Ulrich 2015 included participants with
Bowen’s disease, actinic keratosis, and inflammatory diseases such
as psoriasis and eczema among others (there were no cSCC lesions
included). Wahrlich 2015 provided the only dataset available for
the detection of cSCC, with a prevalence of 18%.
Four studies evaluated conventional swept-source OCT (all with
similar resolutions and tissue penetration capacities), and one eval-
uated HD OCT for diagnosis of melanoma (Gambichler 2015c).
The studies assessed several different thresholds for test positivity
(Table 2). For the detection of melanoma, Gambichler 2015c de-
veloped a new scoring system based on the presence or absence of
risk features and protective features as derived from existing liter-
ature; the method of selection of the numeric cut-off for test pos-
itivity was not described, and Wessels 2015 derived the optimal
attenuation coefficient for detection of melanoma using Youden’s
index. For the diagnosis of BCC, two studies described a num-
ber of OCT characteristics considered indicative of BCC, which
were used by observers to form an overall clinical impression of
BCC or not BCC (Markowitz 2015; Ulrich 2015). Both stud-
ies also reported accuracy for in-person visual examination alone
and for visual examination plus dermoscopic diagnosis. Wahrlich
2015 assessed similar OCT characteristics (Table 2), assigning a
score to each based on the clarity of visualisation of each feature
(named the ’Berlin Score’). Scores based on a separate training set
of lesions were used to identify limit values (T1, T2) to differ-
entiate BCCs from cSCCs, actinic keratosis, and Bowen’s disease
(Wahrlich 2015).
Four studies reported image-based diagnosis with OCT (i.e. diag-
nosis based on OCT scans interpreted remotely from the partic-
ipant concerned); with only Ulrich 2015 describing OCT scans
interpreted in real-time following clinical examination and then
dermoscopy of the lesions. One study described observer qualifi-
cations (with interpretation by a dermatopathologist) (Wahrlich
2015), and three studies described observers as experienced or reg-
ular users of an OCT device (Gambichler 2015c; Ulrich 2015;
Wahrlich 2015). Only Wahrlich 2015 described any test failures
(see Methodological quality of included studies). All studies made
the reference standard diagnosis by histology alone.
Methodological quality of included studies
Overall, study quality was moderate to unclear, with considerable
concerns regarding the clinical applicability of results (Figure 8;
Figure 9).
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Figure 8. Risk of bias and applicability concerns graph: review authors’ judgements about each domain
presented as percentages across included studies.
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Figure 9. Risk of bias and applicability concerns summary: review authors’ judgements about each domain
for each included study.
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Three of the five studies were at low risk of bias for participant se-
lection (Markowitz 2015;Ulrich2015;Wessels 2015); the remain-
ing two did not clearly describe consecutive participant recruit-
ment and one may have used a case-control type design (Wahrlich
2015). All studies had high concern for applicability of the partic-
ipant selection; all scored high concern on both QUADAS items
apart from one recruiting a representative range of non-pigmented
lesions (Ulrich 2015), and one which avoided recruitment of par-
ticipantswithmultiple lesions (Wahrlich 2015).However, all stud-
ies included only lesions selected for excision.
Two studies were at low risk of bias in the index test domain
(Markowitz 2015; Ulrich 2015). Of the remaining three, one did
not enforce blinded interpretation of the index test (OCT in-
terpretation by the dermatopathologist following histology (high
risk,Wahrlich 2015)), one used a data-driven threshold (high risk,
Wessels 2015), and one did not describe the approach to selection
of the numeric threshold used (unclear risk, Gambichler 2015c).
Four studies had high concerns around the applicability of the
index test. All studies reported the thresholds used to define test
positivity; however, in four studies the application of the test was
not clinically applicable due to the use of image-based diagnosis
remote from the study participants. Two studies did not report the
expertise of the clinician interpreting the OCT scan (Markowitz
2015; Wessels 2015). Furthermore, one reported blinding to all
other clinical information (Gambichler 2015c), and two did not
clearly describe what information was provided to test observers
(Markowitz 2015; Wessels 2015).
All studies reported the use of an acceptable reference standard,
but none clearly reported blinding of the reference standard either
to the OCT result or to the referral diagnosis, based on clinical ex-
amination or dermoscopy (although the latter did not contribute
to overall judgements of applicability). For the applicability of the
reference standard, no study reported using expert diagnosis to
provide the final diagnosis of any lesion but only one reported
histopathology interpretation by an experienced dermatopathol-
ogist (Wahrlich 2015); the remainder scored as unclear concerns
regarding applicability of the reference standard.
Three studies were judged at low risk of bias in the flow and
timing domain apart; of the two studies at high risk of bias, Ulrich
2015 reported the exclusion of lesions with missing histology and
Wahrlich 2015 described exclusion of three participants due to
awkward lesion site, different scan ’heights,’ and shadow artefacts
in the discussion section of the paper. None of the other studies
described any failure to successfully image a lesion, raising the
possibility that such cases occurred but were not reported.
For the two studies comparing OCT with visual inspection and
dermoscopy, both reported consecutive diagnoses using each of
the three and blinding between tests was not enforced in either
(this did not contribute to the overall assessment of risk of bias).
The clinical applicability of the application of the tests was of low
concern in Ulrich 2015. Markowitz 2015 scored the same item as
unclear where visual inspection and dermoscopy diagnoses were
both undertaken in-person and OCT interpretation was done re-
motely with no indication as to whether the diagnosis was under-
taken by the same test observer or whether clinical or dermoscopic
images were provided to assist OCT diagnosis.
Findings
All results below refer to the detection of skin cancer in lesions,
not in participants (see Statistical analysis and data synthesis).
Detection of invasive melanoma or atypical
intraepidermal melanocytic variants
Two studies analysed 133 lesions for the detection of 36
melanomas (Figure 10). The single study evaluating conventional
swept-source OCT for the detection of melanoma or atypical in-
traepidermal melanocytic variants in 40 lesions selected for ex-
cision reported sensitivity of 89% (95% CI 52% to 100%) and
specificity of 61% (95%CI 42% to 78%) at an attenuation coeffi-
cient of 5.4mm ¹ (Wessels 2015). In their discussion, the authors
reported an inability to visualise some architectural features (such
as brown globules, rete ridges, or vertical icicle-shaped structures)
useful in making a melanoma diagnosis, due to the insufficient
resolution provided by the conventional OCT system.
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Figure 10. Forest plot of threshold data that could not be pooled for the diagnosis of melanoma and
atypical intraepidermal melanocytic variants (MM + Mis), invasive melanoma alone (MM), basal cell carcinoma
(BCC) and cutaneous squamous cell carcinoma (cSCC). CI: confidence interval; FN: false negative; FP: false
positive; TN: true negative; TP: true positive.
Using HD OCT and their own scoring system for the pres-
ence of recognised OCT characteristics in a sample of 93 lesions,
Gambichler 2015c reported sensitivity of 74% (95% CI 54% to
89%) and specificity of 92% (95% CI 83% to 97%) for the de-
tection of melanoma or atypical intraepidermal melanocytic vari-
ants at a score of -1 or greater and less than -1.5, with sensitivity
increasing to 80% (95% CI 59% to 93%) and specificity to 93%
(95% CI 84% to 98%) for the detection of invasive melanoma
alone; both melanoma in situ lesions included in the study were
misclassified as negative on OCT.
Detection of basal cell carcinoma
All three studies used conventional swept-source OCT for the
detection of 237 BCCs in 396 analysed lesions. Wahrlich 2015
used quantitative scoring of OCT characteristics that resulted in
a sensitivity of 97% (95% CI 82% to 100%) and specificity of
76% (95% CI 53% to 92%) at a Berlin score of 8 or greater,
with lower sensitivity (66%, 95% CI 46% to 82%) and higher
specificity (86%, 95% CI 64% to 97%) at the higher score of 12
or greater (Figure 10). Four of the five false-positive results at 8 or
greater and all three at 12 or greater were cSCC lesions.
Markowitz 2015 and Ulrich 2015 both reported observer diag-
nosis of BCC based on the subjective judgement of the presence
of specified OCT features (Table 2) in clinically challenging non-
pigmented ’pink’ lesions, and compared this to diagnosis by visual
inspection alone and by visual inspection plus dermoscopy (Figure
11). Meta-analysis of the 346 lesions (including 208 BCCs) pro-
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duced a pooled sensitivity forOCTof 95% (95%CI 91% to 97%)
and pooled specificity of 77% (95% CI 69% to 83%). Neither
study reported including any cSCC lesions (benign diagnoses not
described in Markowitz 2015) owing to the fact that both studies
limited participant inclusion to erythematous/pink lesions which
are uncommon presentations for invasive cSCC.
Figure 11. Forest plot of tests: pooled data for the detection of basal cell carcinoma (BCC) using visual
inspection, dermoscopy, and optical coherence tomography (OCT). CI: confidence interval; FN: false negative;
FP: false positive; TN: true negative; TP: true positive.
OCT was significantly more accurate for the diagnosis of BCC in
comparison to visual inspection alone (P= 0.007; Figure 11; Figure
12); visual inspection showing a pooled sensitivity of 80% (95%
CI 55% to 93%) and specificity of 37% (95% CI 24% to 52%).
OCTwas also significantlymore accurate for the diagnosis of BCC
in comparison to visual inspection plus dermoscopy (P < 0.001;
Figure 11; Figure 13); visual inspection and dermoscopy had a
pooled sensitivity of 86% (95% CI 76% to 92%) and specificity
of 55% (95% CI 46% to 63%).
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Figure 12. Summary ROC plot of studies comparing optical coherence tomography (OCT) and visual
inspection for the detection of basal cell carcinoma (BCC).
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Figure 13. Summary ROC plot of studies comparing optical coherence tomography (OCT) and
dermoscopy for the detection of basal cell carcinoma (BCC).
Detection of cutaneous squamous cell carcinoma
One study reported OCT results for the diagnosis of nine cSCCs
among a group of 50 lesions consisting of BCCs (29 lesions),
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actinic keratoses (five lesions), and Bowen’s disease (seven lesions)
(Wahrlich 2015). Using the quantitative scoring of conventional
swept-source OCT characteristics reported above, sensitivity was
56% (95% CI 21% to 86%) and specificity was 100% (91% to
100%) at a score of 8 or greater, with a lower sensitivity using a
score of 12or greater (33%, 95%CI 7% to70%) (Figure 10). BCC
lesions with positive OCT results were considered as true negatives
(not as false positives) as explained in the Statistical analysis and
data synthesis section.
Investigations of heterogeneity
We were unable to undertake formal investigations of heterogene-
ity due to insufficient study numbers.
D I S C U S S I O N
Summary of main results
This review aimed to assess the accuracy of OCT as an aid to
diagnosing melanoma, BCC, or cSCC in adults. We included
five studies evaluating OCT, two of which also evaluated visual
inspection and visual inspection plus dermoscopy (Summary of
findings).
Studies were generally of moderate to unclear methodological
quality, and poor in terms of the applicability of their results to a
clinical setting. For risk of bias, therewas a lack of clarity of descrip-
tion of several different items across the studies including: recruit-
ment methods, study design, threshold selection, and particularly
blinding of the reference standard to the index test result. Appli-
cability concerns were almost universally high for participants and
index test, due to unrepresentative samples and the use of image-
based OCT interpretation undertaken remotely from study par-
ticipants. There was limited information provided regarding the
qualifications of the clinicians undertaking and interpreting the
tests. All studies established the final diagnoses by histology; how-
ever, reference standard interpretation was poorly described.
For the detection of melanoma, the paucity of studies, small sam-
ple sizes, and differences in the tests made summary statements
regarding accuracy impossible. Conventional OCT using a data-
driven threshold in a sample with a high prior history ofmelanoma
(61%) produced a sensitivity of 89% (95% CI 52% to 100%)
and specificity of 61% (95% CI 42% to 78%); however, low res-
olution was problematic. HD OCT using a scoring system based
on OCT characteristics misclassified the two included melanoma
in situ lesions as OCT negative, leading to a sensitivity of 74%
(95% CI 54% to 89%) and specificity of 92% (95% CI 83% to
97%) for the detection of melanoma or atypical intraepidermal
melanocytic variants. We found no data that compared OCT to
standard diagnostic practice for the detection of melanoma.
For the detection of BCC, two studies evaluated observer diagnosis
with conventional OCT using the same diagnostic criteria, in sim-
ilar populations of participants. Meta-analysis of the 346 lesions
resulted in a pooled sensitivity of 95% (95% CI 91% to 97%)
and specificity of 77% (95% CI 69% to 83%). In both studies,
OCT was statistically significantly more sensitive and more spe-
cific compared to visual inspection alone (sensitivity 15% higher
and specificity 40%higher) and compared to visual inspection plus
dermoscopy (sensitivity 9% higher and specificity 22% higher).
Summary of findings translated these estimates to a hypothetical
cohort of 1000 lesions at the mean prevalence of BCC of 60%.
A sensitivity for OCT of 95% would miss 31 BCCs; a reduction
from those that would be missed by using visual inspection alone
in these lesions of 91 and a reduction from those that would be
missed by visual inspection plus dermoscopy of 53 BCCs. A speci-
ficity of 77% for OCT would result in 93 false-positive results;
a reduction in unnecessary excisions of 159 compared to using
visual inspection alone and of 87 compared to using visual inspec-
tion plus dermoscopy. Both studies analysed clinically challenging
’pink’ lesions; however, BCC prevalence was very high.
One further study which developed an OCT score (Berlin score)
to determine the presence of BCC reported similar sensitivity and
specificity in at least one threshold but it was unclear whether these
results would be reproducible. Producing the only evidence for
the detection of cSCC, this study suggested that OCT was poor
in its ability to discriminate between BCC and cSCC when the
’Berlin score’ was used. However, the study included few cSCC
cases that were retrospectively selected as ’controls’ against the
detection of BCC cases, and so was at high risk of having produced
biased results. No studies evaluated HD OCT technology for the
detection and discrimination of keratinocyte skin cancers.
Strengths and weaknesses of the review
The strengths of this review included an in-depth and comprehen-
sive electronic literature search, systematic reviewmethods includ-
ing double extraction of papers by both clinicians and methodol-
ogists, and contact with authors to allow study inclusion or clarify
data. A clear analysis structure was planned to allow test accuracy
in different study populations to be estimated and a detailed and
replicable analysis of methodological quality was undertaken.
The main concerns for the review regarding the clinical applica-
bility of study findings to a normal practice setting, both in terms
of using more highly selected study populations than are encoun-
tered in practice and commonly interpreting OCT scans remotely
from the patient. While OCT could be used in clinical practice to
examine several lesions in a single patient, studies that did so were
downgraded in quality appraisal due to the potential bias intro-
duced by including patients with many lesions (Appendix 4). This
was compounded by poor reporting of study conduct, especially
with regard to the reference standard and lack of clear prespecifi-
cation of the diagnostic threshold for test positivity. The inability
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of the ’Berlin score’ to differentiate BCC from cSCC and the lack
of inclusion of cSCC lesions in the two studies of observer diag-
nosis without the aid of the score raised questions over the abil-
ity of observers to discriminate between these lesion types using
OCT. Furthermore, no study reported the presence or absence of
index test failures, for example due to inadequate imaging quality
or inaccessibility of lesions, and so it is unclear how frequently
one would encounter uninterpretable scans when OCT is used in
clinical practice.
Many of the studies excluded from this review were derivation
studies or assessed the accuracy of individual OCT characteristics
rather than the overall ability of the test to diagnose a particular
skin cancer. This is indicative of the relatively novel nature of the
test and its application to skin cancer diagnosis.
Applicability of findings to the review question
The data included in this review are unlikely to be generally ap-
plicable to the clinical setting. Narrow definitions of the eligible
study populations, high disease prevalence, the use of remote im-
age-based test interpretation, and lack of description of the refer-
ence standards used may restrict applicability and transferability
of results in practice.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Insufficient data are available to determine the accuracy of optical
coherence tomography (OCT) for the detection of melanoma or
cutaneous squamous cell carcinoma (cSCC). For the detection of
basal cell carcinoma (BCC), initial data on OCT shows poten-
tial increased sensitivity and specificity compared with visual in-
spection and dermoscopy; however, the small number of studies
and varying methodological quality means that no implications to
guide clinical practice can currently be drawn.
Implications for research
Further prospective evaluation of OCT is warranted in popu-
lations with a clinical suspicion of melanoma, and in popula-
tions with a clinical suspicion of keratinocyte skin cancer. For
melanoma, these studies should evaluate high-definition (HD)
OCT in comparison to visual inspection and dermoscopy alone,
in a standard healthcare setting and with a clearly defined and
representative population of participants with a range of different
lesion types to whom study results can be applied in practice. For
a full and proper evaluation of the ability of OCT to detect ker-
atinocyte skin cancers, similar comparisons should recruit study
populations that include sufficient numbers of participants with
suspected BCC and cSCC in order to assess whether the test is
able to discriminate adequately between the different forms of skin
cancer.
Given that reflectance confocal microscopy (RCM) is likely the
closest direct ’competitor’ test to OCT, a comparison with RCM
in lesions that are equivocal following visual inspection and der-
moscopy may also be warranted.
The clinical pathway, or referral process, for study eligibility must
be clearly described in order to establish the participant groups
to whom study results can be applied in practice. A multi-cen-
tred approach would allow confirmation that results are replicable
across centres and that the technology can be implemented across
a health service. Prospective recruitment of a consecutive series of
participants, with test interpretation blinded to the reference stan-
dard diagnosis and using prespecified and clearly defined diagnos-
tic thresholds for determining test positivity, are easily achieved.
In order to be generalisable to clinical practice, studies should per-
form OCT scans within the clinical pathway, with interpretation
made in the presence of participants and by clinicians experienced
with skin cancer diagnosis and OCT. Points-based ’rules’ to assist
diagnosis require proper validation in an appropriate clinical set-
ting and would allow a standardised approach to diagnosis. Clear
identification of the qualifications and level of observer training
and experience needed to achieve good results is also required.
Systematic follow-up of non-excised lesions avoids over-reliance
on a histological reference standard and allows results to be more
generalisable to routine practice. Any future research study needs
to be clear about the diagnostic pathway followed by study par-
ticipants prior to study enrolment, and reporting should conform
to the updated Standards for Reporting of Diagnostic Accuracy
(STARD) guideline (Bossuyt 2015).
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Gambichler 2015c
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: NR
Country: Germany
Funding: Agfa Healthcare
Patient characteristics and set-
ting
Inclusion criteria: people scheduled formelanocytic skin lesion excision because of cosmetic reasons
or suspicion of CM
Setting: secondary (dermato-oncology)
Prior testing: clinical inspection + dermoscopy
Exclusion criteria: presence of frank ulceration, marked hyperkeratosis, histopathological confir-
mation of non-melanocytic skin lesion
Sample size (participants): number eligible: NR; number included: 64
Sample size (lesions): number eligible: NR; number included: 93
Participant characteristics: none reported
Lesion characteristics: mean Breslow thickness of correctly identified melanoma (all invasive) 1.2
(SD 1.1) mm; 20 lesions. Mean Breslow thickness of missed melanoma (false negatives) 0.29 (SD
0.23) mm for 5 invasive MM, plus melanoma in situ
Index tests HD-OCT (Skintell; Agfa, Belgium); resolution 3 µm lateral by 5 µm axial; tissue penetration 570
µm; centre wavelength 1300 nm; the 3D images of the scans showing the best quality (i.e. no
artefacts) were chosen
Diagnostic threshold: new scoring system based on previously describedmicromorphological HD-
OCT correlates of melanocytic skin lesions (Boone 2014; Picard 2013), and from RCM (Segura
2009), and conventional OCT studies (Gambichler 2007); a score ≥ -1 indicated melanoma, a
score ≥ -1.5 indicated benign melanocytic skin lesion, i.e. melanoma present if score ≥ -1 and < -
1.5
Method of diagnosis: image-based
Prior test data available: none; blinded to clinical examination and dermoscopy
Diagnosis based on: single (1)
Observer qualifications: NR; presumed dermatologist
Experience in practice: NR
Experience with index test: high; described as “OCT-experienced investigator”
Any other detail: OCT scoring based on “predominant presence of the following risk (+) and/or
protective (-) features… (i) HD-OCT en-face mode - typical basal cells/clusters (-1), edged papillae
(-1), honeycomb/cobblestone pattern (-1), large roundish pagetoid cells (+1), atypical cell clusters
in the dermoepidermal junction (DEJ) (+1), totally disarranged epidermal/dermal pattern (+1); (ii)
HD-OCT slice mode - clearly demarcated DEJ (-0.5), finger-shaped elongated rete ridges (-0.5)
, bright bizarre dermal horizontal streaks (+0.5), large vertical icicle-shaped structures (+0.5). The
total score is the sum of the aforementioned sub-scores for the various particular criteria.”
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Gambichler 2015c (Continued)
Target condition and reference
standard(s)
Type of reference standard: histology alone
Details: lesions completely excised and processed for routine haematoxylin and eosin staining, plus
immunohistochemistry for S100 and MART/Melan-A
Disease positive: 27; disease negative: 66
Target condition (final diagnoses): invasive melanoma: 25; melanoma in situ: 2. Benign nevi: 66
(23 compound naevi, 20 junctional naevi, 10 dermal naevi, 9 dysplastic naevi, 2 nevoid lentigo and
2 blue naevi)
Flow and timing Index test to reference standard interval: consecutive; “after HD-OCT assessments, the tumours
were completely excised.”
Interval between index tests: N/A
Exclusions: none reported
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included participants
and chosen study setting appro-
priate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Unclear High
DOMAIN 2: Index Test Optical coherence tomography
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
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Gambichler 2015c (Continued)
If a threshold was used, was it
pre-specified?
Unclear
Unclear High
DOMAIN 2: Index Test Dermoscopy
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis? (Does
not contribute to ’Risk of bias’
judgement)
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
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Gambichler 2015c (Continued)
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than 1 algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
Markowitz 2015
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: NR
Country: USA
Funding: study was sponsored by Michelson Diagnostics
Patient characteristics and set-
ting
Inclusion criteria: consecutive participants with clinically challenging pink lesions on the head or
neck and that were suspicious for BCC and therefore to be biopsied to rule BCC in or out; also
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Markowitz 2015 (Continued)
required to be eligible for Mohs surgery; maximum of 3 lesions per participant
Setting: secondary (general dermatology)
Prior testing: clinical or dermoscopic suspicion of malignancy; decision to perform diagnostic
biopsy was made following clinical, dermoscopic, and OCT evaluation
Setting for prior testing: secondary (general dermatology)
Exclusion criteria: previous history of skin cancer/prior treatment at site; history of evidence of
metastases, topical actinic therapy within 8 weeks prior to evaluation, other skin conditions within
lesion
Sample size (participants): number included: 100
Sample size (lesions): number included: 115
Participant characteristics: none reported
Lesion characteristics: all head and neck
Index tests Visual inspection: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
Diagnostic threshold: observer diagnosis of BCC; clinically challenging lesions defined as “lesions
that did not have the usual characteristics of BCC, such as ulceration, bleeding, crusting, isolated
pink scaly patches, or pearly papules”; also took into account patient’s clinical history of a non-
healing area of concern or the clinician’s inability to rule out BCC
Diagnosis based on: unclear; likely in clinic diagnoses (number NR)
Observer qualifications: not described; likely dermatologist
Experience in practice: not described
Experience with index test: not described
Dermoscopy: 2-step algorithm referenced to Marghoob 2010 and Malvehy 2002
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
Diagnostic threshold: dermoscopic features consistent with BCC: arborised vessels, pink white
shiny background, blue/grey ovoid nests, ash leaf pattern, dot-globular-like pattern, spoke wheel,
and crystalline-like structures
Test observers: as described for visual inspection
OCT: no algorithm; multi-beam swept-source frequency domain (VivoSight; Michelson Diagnos-
tics, UK); resolution axial 10 µm, lateral 7.5 µm; tissue penetration 2000 µm; centre wavelength
1305 nm; “multi-1” setting automatically provided 60 lateral scans of 6 mm length every 100 µm
Method of diagnosis: image-based; OCT scans obtained at time of visual inspection and dermo-
scopic diagnoses and read within 1 week of the diagnostic biopsy
Prior test data: unclear; clinical and dermoscopic images obtained but not clear whether provided
to OCT interpreter
Diagnostic threshold: observer diagnosis based on features described in previous studies (Maier
2013; Ulrich 2015; Wahrlich 2015): “epidermis was analysed for protrusions into the dermis with
shadowing; the epidermal-dermal junction for lack of definition or rupturing; and the dermis for
signal-poor ovoid structures, dark rims, ovoid structures with bright centres, dilated vessels, black
areas or cysts, bright stroma, and/or small ovoid signal-poor structures (“fish shoal”)”
Test observers: not described
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: none reported
Disease positive: 70 BCC; disease negative: 45
Target condition (final diagnoses): BCC: 70. ’Benign’ diagnoses: 45 (not further described)
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Markowitz 2015 (Continued)
Flow and timing Excluded participants: none reported
Time interval to reference test: appeared consecutive; Figure 2described theOCTscans undertaken
at the time of clinical examination and dermoscopy; diagnostic biopsy was then performed and the
“OCT scan is read within a week, prior to obtaining the results of the diagnostic biopsy.”
Comparative Time interval between index test(s): consecutive; clinical, dermoscopic and OCT images taken
at the same time; clinical and dermoscopic diagnoses made at the time of taking the images while
OCT scans were read within 1 week
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included participants
and chosen study setting appro-
priate?
Unclear
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Optical coherence tomography
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low High
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DOMAIN 2: Index Test Visual inspection
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Unclear
DOMAIN 2: Index Test Test group E
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
DOMAIN 2: Index Test Test group F
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
DOMAIN 2: Index Test Test group G
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
DOMAIN 2: Index Test Test group H
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
Low Unclear
DOMAIN 2: Index Test Test group J
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
DOMAIN 2: Index Test Test group K
Was the test applied and inter-
preted in a clinically applicable
manner?
Unclear
DOMAIN 2: Index Test Test group L
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
DOMAIN 2: Index Test Test group M
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis? (Does
not contribute to ’Risk of bias’
judgement)
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
54Optical coherence tomography for diagnosing skin cancer in adults (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Markowitz 2015 (Continued)
If more than 1 algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than 1 month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
Unclear
Low Unclear
Ulrich 2015
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: April 2013 to March 2014
Country: Germany
Funding: study was funded by Michelson Diagnostics Ltd. (MDL)
Patient characteristics and set-
ting
Inclusion criteria:peoplewith non-pigmentedpink lesionswith clinical suspicionof BCCrequiring
biopsy for diagnostic confirmation. Pink lesions defined as clinically unclear erythematous papule
or plaque; either reddish macules, patches or small papules with or without scale (only lesions with
histology included)
Setting:multi-centre study; authors’ institutions included 4Dermatology departments and 3 private
dermatology clinics
Prior testing: inclusionwas based on clinical assessment alone, without the assistance of dermoscopy
Setting for prior testing: unspecified
Exclusion criteria: unequivocal appearance/diagnosis. Lesions with the typical clinical appearance
of BCC on clinical examination (such as the presence of a pearly border, central ulceration and
obvious telangiectasias), as well as pigmented lesions, were excluded from the protocol. People with
unstable or uncontrolled clinically significant medical conditions were excluded. 21 Lesions with
missing histology also excluded
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Sample size (participants): number eligible: 164; number included: 155
Sample size (lesions): number eligible: 256; number included: 235 (different sets of 231 lesions
were available for each test)
Participant characteristics: median age: 70 years (range 33-90 years)
Lesion characteristics: head/neck: 41%; upper body 48.8%
Index tests Visual inspection: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: N/A, in-person diagnosis
Diagnostic threshold: observer diagnosis of BCC; pink or red lesions that could be macules,
patches, or small papules with or without scale
Diagnosis based on: single observer; (number NR; 6 centres participated)
Observer qualifications: probably dermatologists given authors institutions
Experience in practice: not described
Experience with index test: not described
Dermoscopy: no algorithm
Method of diagnosis: in-person diagnosis
Prior test data: clinical examination or case notes (or both)
Diagnostic threshold: observer diagnosis; “A scattered vascular global pattern with loose haphazard
distribution. Shiny white to red structures with or without chrysalis-like structures. Small fine
telangiectasias appearing as fine, kinked vessels of small calibre, with length < 1 mm in superficial
BCC and larger arborizing vessels in more invasive BCC (nodular/infiltrative);” referenced to
Marghoob 2012.
Test observers: as described for visual inspection (above)
Any other detail: after clinical examination dermoscopy was carried out using a Dermlite ProHr
(3Gen Inc., San Juan Capistrano, CA, USA), attached to a Sony Cybershot DSC-W710 camera
(Sony, Tokyo, Japan) (supplied by MDL). As polarised light was used, no preparation of the area
under examination was necessary
OCT: no algorithm; multi-beam swept-source frequency domain; VivoSight (MDL); resolution
axial 10 µm, lateral 7.5 µm; tissue penetration 2000 µm; centre wavelength 1305 nm; the function
’multi-1’ setting automatically provided 60 lateral scans of 6 mm length every 100 µm
Method of diagnosis: in-person; OCT images were assessed following dermoscopy by naked eye
for features affecting the epidermis, DEJ, and dermis
Prior test data available: clinical examination and dermoscopy
Diagnostic threshold: observer diagnosis; based on “Epidermis: protrusions into the dermis with
shadowing; dermoepidermal junction: lack of definition or rupturing; and dermis: signal-poor ovoid
structures, dark rims, ovoid structures with bright centres, dilated vessels, black areas or cysts, bright
stroma and small ovoid signal-poor structures (’fish shoal’).” Paper cited Boone 2012 as having been
published since the study was designed.
Observers: as above. All centres described as regular users of OCT, with ≥ 3 months of practical
experience with the device. Nonetheless, all centres received training before participating in the
study
Target condition and reference
standard(s)
Reference standard: histological diagnosis alone
Details: a biopsy or excision of the lesion was taken
Disease positive: 141; disease negative: 94
Target condition (final diagnoses): BCC: 141. ’Benign’ diagnoses: 94 (32 AK, 17 BD, 6 SK, 6
inflammatory diseases (psoriasis, eczema, etc.), 34 other including sebaceous hyperplasia, dermal
naevus, microcystic adnexal carcinoma)
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NB: different sets of 231 lesions were recorded for each test, therefore the number diseased per 2×2
varied
Flow and timing Excluded participants: histology was missing for 21 lesions, and 1 case had a combination of both
BCC and SK or AK, leaving 235 lesions for analysis in the ITT group
Time interval to reference test: consecutively done after index test, “All diagnostic steps had to be
completed before histological confirmation was made.”
Comparative Time interval between index test(s): consecutive
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included participants
and chosen study setting appro-
priate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Optical coherence tomography
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
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DOMAIN 2: Index Test Visual inspection
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
Low Low
DOMAIN 2: Index Test Test group E
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
DOMAIN 2: Index Test Test group F
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
DOMAIN 2: Index Test Test group G
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
DOMAIN 2: Index Test Test group H
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
DOMAIN 2: Index Test Dermoscopy
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
Yes
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For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
Low Low
DOMAIN 2: Index Test Test group J
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
DOMAIN 2: Index Test Test group K
Was the test applied and inter-
preted in a clinically applicable
manner?
Yes
DOMAIN 2: Index Test Test group L
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
DOMAIN 2: Index Test Test group M
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
DOMAIN 3: Reference Standard
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Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis? (Does
not contribute to ’Risk of bias’
judgement)
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
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If more than 1 algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
High
DOMAIN 5: Comparative
Was each index test result in-
terpreted without knowledge of
the results of other index tests
or testing strategies?
No
Was the interval between ap-
plication of the index tests less
than 1 month?
Yes
Were all tests applied and inter-
preted in a clinically applicable
manner?
Yes
Low Low
Wahrlich 2015
Study characteristics
Patient sampling Study design: unclear
Data collection: retrospective
Period of data collection: September 2011 to June 2012
Country: Germany
Funding: none; OCT device provided by Michelson Diagnostics
Patient characteristics and set-
ting
Inclusion criteria: participants with non-melanoma skin cancer including BCC or other skin
lesions; phase 1 of study excluded as student observers
Setting: secondary (Dermatology)
Prior testing: unclear
Exclusion criteria: preoperated or ulcerated lesions
Sample size (participants): number eligible: NR; number included: 50
Sample size (lesions): number eligible: 50; number included: 50
Participant characteristics: mean age 62.8 years; 46% men
Lesion characteristics: none reported
Index tests OCT: ’Berlin score’, developed by authors ’prior to the start of the study’ based on data from other
study groups; multi-beam swept-source frequency domain; VivoSight (MDL); resolution axial 10
µm, lateral 7.5 µm; tissue penetration 2000 µm; centre wavelength 1305 nm; performed using
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free-run and multi-slice functions on an area of 6 × 6 × 2 mm. Affected areas were shaved (hairy
areas) or pretreated with Sellotape (scaly lesions) as required
Diagnostic threshold: 2 thresholds assessed, Berlin score ≥ 8 (T1 limit) and of ≥ 12 (T2 limit)
Method of diagnosis: unclear
Prior test data available: unclear; appeared that following histological diagnosis the histologist
then retrospectively examined the OCT images
Diagnosis based on: single (1)
Observer qualifications: dermatopathologist; described as “dermatological specialist/der-
matopathologist and expert familiar with OCT”
Experience in practice: high
Experience with index test: high
Other detail: BCC features subdivided into major (dark borders underneath the tumour, hypore-
flective nests and ovoid structures) and minor criteria (disruption of DEJ and cysts). Presence of
feature classed between 0 (absent) and 3 (clearly recognisable structure); visible (2) and less visible (1)
structures could not clearly be allocated. Criteria were added to a cumulative score with a maximum
of 24 points. Binary logistic regression identified limit values (T1, T2) to differentiate BCC from
’others’ using phase 1 of the study (100 BCC and 30 ’other’ skin diseases; using student observers)
. Main diagnostic features based on already existing data of other study groups (Khandwala 2010;
Mogensen 2009a; Sabban 2004; Vogt 2003; Zhao 2008).
Target condition and reference
standard(s)
Type of reference standard: histology alone
Details: biopsy or excision
Disease positive: 29; disease negative: 21
Target condition (final diagnoses): BCC 29. cSCC 9; BD 7; AK 5
Flow and timing Index test to reference standard interval: consecutive; OCT described as followed by excision or
biopsy
Exclusions: discussion reported exclusion of 3 participants due to anatomical position, different
scan ’heights’ and shadow artefacts
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Unclear
Was a case-control design
avoided?
Unclear
Did the study avoid inappropri-
ate exclusions?
Yes
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Are the included participants
and chosen study setting appro-
priate?
No
Did the study avoid including
participants with multiple le-
sions?
Yes
Unclear High
DOMAIN 2: Index Test Optical coherence tomography
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
No
If a threshold was used, was it
pre-specified?
Yes
High High
DOMAIN 2: Index Test Dermoscopy
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Yes
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
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Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis? (Does
not contribute to ’Risk of bias’
judgement)
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Yes
Unclear Low
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
No
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than 1 algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
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High
Wessels 2015
Study characteristics
Patient sampling Study design: case series
Data collection: prospective
Period of data collection: November 2011 to April 2012
Country: Netherlands
Funding: none declared
Patient characteristics and set-
ting
Inclusion criteria: consecutive participants with pigmented (melanocytic) lesions with clinical
suspicion of melanoma during routine skin cancer screening, from whom an excision had to be
taken in the outpatient clinic of the Netherlands Cancer Institute in Amsterdam
Setting: secondary; outpatient clinic
Prior testing: clinical assessment during routine skin cancer screening
Exclusion criteria: none reported
Sample size (participants): number eligible: NR; number included: 33
Sample size (lesions): number eligible: NR; number included: 40
Participant characteristics:mean age 46 (SD 16) years; 42%men; history of melanoma (20 (61%)
);
Lesion characteristics: all lesions rated as clinically suspicious on naked eye and 19 also had
dermoscopic suspicion; lesion site: trunk and neck (28 (70%)), arms and legs (12 (30%)); Fitzpatrick
type 1 (2 (6%)), type 2 (15 (46%)), type 3 (15 (46%)), type 4 (1 (3%)). Mean attenuation coefficient
of benign lesions was 5.49 mm ¹ and of melanomas was 4.28 mm ¹
Index tests OCT: no algorithm; swept-source OCT (Santec Inner Vision 2000); resolution axial 10 µm, lateral
20 µm; tissue penetration 2000 µm; centre wavelength 1300 nm; for each lesion 5 2D and 1
3D OCT scans were recorded, plus 5 2D scans from healthy skin next to the lesion. Attenuation
coefficient could not be identified in 20 2D OCT scans due to thin layer thickness
Diagnostic threshold: investigated accuracy of 2 morphological features on 3D scans (absence of
clear DEJ and no lower boundary of lesion visible) and attenuation coefficient based on 2D scans
5.4 mm ¹ (optimal threshold estimated via Youden index)
Method of diagnosis: image-based
Prior test data available: unclear; “All scans were stored to be analysed at a later date by one
investigator (RW) blinded for the pathology report.”
Diagnosis based on: single (1)
Observer qualifications: unclear; investigator institution Department of Surgery
Experience in practice: not described
Experience with index test: not described
Other detail: epidermal layer thickness and the attenuation coefficient (µoct mm ¹) were mea-
sured. “The attenuation coefficient is the decrease in light intensity per millimetre; measurement
was performed as described before (Faber 2004) using custom written software (LabVIEW 2011;
National Instruments, Austin, TX, USA).”
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Target condition and reference
standard(s)
Type of reference standard: histology alone
Details: excision; all stained sections were reviewed by 1 pathologist
Disease positive: 9;disease negative: 31
Target condition (final diagnoses): invasive melanoma 7; melanoma in situ 2. Benign nevi: 31
(24 compound nevi, 5 dysplastic nevi)
Flow and timing Index test to reference standard interval: consecutive; “After OCT-imaging, excision was per-
formed.”
Exclusions: none reported
Comparative
Notes -
Methodological quality
Item Authors’ judgement Risk of bias Applicability concerns
DOMAIN 1: Patient Selection
Was a consecutive or random
sample of patients enrolled?
Yes
Was a case-control design
avoided?
Yes
Did the study avoid inappropri-
ate exclusions?
Yes
Are the included participants
and chosen study setting appro-
priate?
No
Did the study avoid including
participants with multiple le-
sions?
No
Low High
DOMAIN 2: Index Test Optical coherence tomography
Were the index test results in-
terpreted without knowledge of
the results of the reference stan-
dard?
Yes
If a threshold was used, was it
pre-specified?
No
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High High
DOMAIN 2: Index Test Dermoscopy
For studies reporting the ac-
curacy of multiple diagnostic
thresholds, was each threshold
or algorithm interpreted with-
out knowledge of the results of
the others?
No
Was the test applied and inter-
preted in a clinically applicable
manner?
No
Were thresholds or criteria for
diagnosis reported in sufficient
detail to allow replication?
Yes
Was the test interpretation car-
ried out by an experienced ex-
aminer?
Unclear
DOMAIN 3: Reference Standard
Is the reference standards likely
to correctly classify the target
condition?
Yes
Were the reference standard re-
sults
interpreted without knowledge
of the results of the index tests?
Unclear
Were the reference standard re-
sults
interpreted without knowledge
of the referral diagnosis? (Does
not contribute to ’Risk of bias’
judgement)
Unclear
Expert opinion (with no his-
tological confirmation) was not
used as a reference standard
Yes
Was histology interpretation
carried out by an experienced
histopathologist or by a der-
matopathologist?
Unclear
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Unclear Unclear
DOMAIN 4: Flow and Timing
Was there an appropriate inter-
val between index test and ref-
erence standard?
Yes
Did all patients receive the same
reference standard?
Yes
Were all patients included in the
analysis?
Yes
If the reference standard in-
cludes clinical follow-up of
borderline/benign appearing le-
sions, was there a minimum
follow-up following application
of index test(s) of at least: 3
months for melanoma or cSCC
or 6 months for BCC?
If more than 1 algorithm was
evaluated for the same test, was
the interval between applica-
tion of the different algorithms
1 month or less?
Low
2D: two dimensional; 3D: three dimensional; AK: actinic keratosis; BCC: basal cell carcinoma; BD: Bowen’s disease; CM: cutaneous
melanoma; cSCC: cutaneous squamous cell carcinoma;DEJ: dermoepidermal junction;HD-OCT: high-definition optical coherence
tomography; ITT: intention to test; MM: malignant melanoma; N/A: not applicable; NR: not reported; OCT: optical coherence
tomography; RCM: reflectance confocal microscopy; SD: standard deviation; SK: seborrhoeic keratosis.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Alawi 2013 Exclude on index test
OCT used to determine surgical margins
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Bechara 2004 Exclude on sample size
only 3 BCCs
Exclude if individual lesion characteristics
Boone 2014 Exclude if individual lesion characteristics
Boone 2015a Exclude on study population
included healthy volunteers; also preselected AK and SCC
Exclude if derivation study
Study developed a diagnostic algorithm for HD-OCT (no independent test population)
Boone 2015b Exclude if derivation study
Exclude on 2×2 data
Boone 2016 Exclude if derivation study
Appeared to be first study assessing optical properties of HD-OCT rather than diagnosis by morphological
characteristics
Brudermanns 2008 Exclude not a primary study
Comment on Gambichler 2007
Calin 2013 Exclude not a primary study
Systematic review
Coleman 2013 Exclude on study population
No results for benign lesions
Cunha 2011 Exclude on study population
All BCC cases (no benign lesions)
de Boer 2016 Exclude not a primary study
Systematic review (not addressing OCT)
de Giorgi 2005 Exclude if individual lesion characteristics
Exclude if derivation study
Evans 2014 Exclude not a primary study
Editorial review
Forsea 2010 Exclude on sample size
Exclude if derivation study
Gambichler 2007 Exclude if derivation study. First study of OCT in skin cancer; looking at features of OCT and comparing
with histology
Exclude on 2×2 data - not enough data to complete 2x2 table
Gambichler 2014 Exclude on study population
BCCs only included
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Gambichler 2015b Exclude if individual lesion characteristics
Exclude if derivation study
Hinz 2011 Exclude on target condition
Assessed tumour thickness only
Hussain 2015 Exclude not a primary study
Systematic review
Hussain 2016 Exclude on study population
People undergoing follow-up for recurrent BCC
Exclude on target condition
Recurrent BCC
Jorgensen 2008 Exclude on index test
Machine learning OCT
Maier 2013 Exclude on study population - BCCs only included (no disease-negative included)
Marneffe 2016 Exclude on study population
AK, SCC, normal skin
Meyer 2014 Exclude on target condition
Detection of lesion thickness only
Mogensen 2009a Exclude on study population
Differentiating NMSC from normal skin
Exclude on reference standard
Not clearly reported; described as ’clinically diagnosed’
Mogensen 2009b Exclude not a primary study
Review/opinion paper
Mogensen 2009c Exclude on target condition
Precision of tumour size measurements
Moraes 2015 Exclude if individual lesion characteristics
Olmedo 2006 Exclude on study population - BCCs only included (no disease-negative included)
Olsen 2015 Exclude not a primary study
Systematic review
Picard 2013 Exclude not a primary study
Case report
Reggiani 2015 Exclude not a primary study
Systematic review
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Strasswimmer 2004 Exclude on sample size
2 cases presented
Exclude if derivation study
Ulrich 2014 Exclude conference abstract
Included full paper (Ulrich 2015)
Welzel 1998 Exclude on 2×2 data
Not test accuracy; preliminary study of OCT
Wessels 2013 Exclude conference abstract
Included full paper (Wessels 2015)
Zakharov 2014 Exclude conference abstract
Zakharov 2015 Exclude on index test
Ex-vivo diagnosis not relevant to the review
AK: actinic keratosis; BCC: basal cell carcinoma; HD-OCT: high-definition optical coherence tomography; NMSC: non-melanoma
skin cancer; OCT: optical coherence tomography; SCC: squamous cell carcinoma.
Characteristics of studies awaiting classification [ordered by study ID]
Cheng 2016
Study characteristics
Patient sampling Consecutive group of people at moderate to very high risk of melanoma presenting to Melanoma
Institute Australia from April 2014 to March 2015 with possible sBCC based on clinical and
dermoscopic findings
Patient characteristics and set-
ting
168 lesions; 52% sBCC, 26% other BCC variants and remaining lesions were AK, squamous cell
carcinoma in situ, other benign inflammatory processes, and 2 other malignant tumours
Index tests Visual examination, dermoscopy, OCT
Target condition and reference
standard(s)
BCC, histology (punch biopsy)
Flow and timing Biopsy performed immediately after OCT scanning
Comparative No
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Notes Comparison of 3 observers with varying levels of OCT experience. Confidence in the diagnosis also
recorded
Olsen 2016
Study characteristics
Patient sampling Retrospective study of image bank from scans performed 2010 to 2015
Patient characteristics and set-
ting
142 good-quality OCT images of BCC, AK, and normal skin (good quality defined as: minimal
shadowing artefacts from hairs, hyperkeratosis, and crustae)
Index tests OCT
Target condition and reference
standard(s)
BCC, histology
Flow and timing Not reported
Comparative No
Notes Published August 2016 but not identified in update search; awaiting author communication to
allow inclusion (contacted 7 July 2017)
AK: actinic keratosis; BCC: basal cell carcinoma; OCT: optical coherence tomography; sBCC: superficial basal cell carcinoma.
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D A T A
Presented below are all the data for all of the tests entered into the review.
Tests. Data tables by test
Test
No. of
studies
No. of
participants
1 Optical coherence tomography
(OCT) attenuation coefficient
5.4 mm ¹ (malignant
melanoma (MM) + melanoma
in situ (MiS))
1 40
2 High-definition optical
coherence tomography
(HD-OCT) Gambichler score
≥ -1 (MM + MiS)
1 93
3 HD-OCT - Gambichler score ≥
-1 (MM)
1 93
4 OCT observer diagnosis (basal
cell carcinoma (BCC))
2 346
5 Visual inspection observer
diagnosis (BCC)
2 346
6 Dermoscopy observer diagnosis
(BCC)
2 346
7 OCT Berlin score ≥ 8 (BCC) 1 50
8 OCT Berlin score ≥ 12 (BCC) 1 50
9 OCT Berlin score ≥ 8
(cutaneous squamous cell
carcinoma (cSCC))
1 50
10 OCT Berlin score ≥ 12 (cSCC) 1 50
Test 1. Optical coherence tomography (OCT) attenuation coefficient 5.4 mm
¹ (malignant melanoma (MM) + melanoma in situ (MiS)).
Review: Optical coherence tomography for diagnosing skin cancer in adults
Test: 1 Optical coherence tomography (OCT) attenuation coefficient 5.4 mm (malignant melanoma (MM) + melanoma in situ (MiS))
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wessels 2015 8 12 1 19 0.89 [ 0.52, 1.00 ] 0.61 [ 0.42, 0.78 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 2. High-definition optical coherence tomography (HD-OCT) Gambichler score ≥ -1 (MM + MiS).
Review: Optical coherence tomography for diagnosing skin cancer in adults
Test: 2 High-definition optical coherence tomography (HD-OCT) Gambichler score ≥ 1 (MM + MiS)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Gambichler 2015c 20 5 7 61 0.74 [ 0.54, 0.89 ] 0.92 [ 0.83, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 3. HD-OCT - Gambichler score ≥ -1 (MM).
Review: Optical coherence tomography for diagnosing skin cancer in adults
Test: 3 HD-OCT Gambichler score≥ 1 (MM)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Gambichler 2015c 20 5 5 63 0.80 [ 0.59, 0.93 ] 0.93 [ 0.84, 0.98 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 4. OCT observer diagnosis (basal cell carcinoma (BCC)).
Review: Optical coherence tomography for diagnosing skin cancer in adults
Test: 4 OCT observer diagnosis (basal cell carcinoma (BCC))
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Markowitz 2015 65 9 5 36 0.93 [ 0.84, 0.98 ] 0.80 [ 0.65, 0.90 ]
Ulrich 2015 132 23 6 70 0.96 [ 0.91, 0.98 ] 0.75 [ 0.65, 0.84 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 5. Visual inspection observer diagnosis (BCC).
Review: Optical coherence tomography for diagnosing skin cancer in adults
Test: 5 Visual inspection observer diagnosis (BCC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Markowitz 2015 44 23 26 22 0.63 [ 0.50, 0.74 ] 0.49 [ 0.34, 0.64 ]
Ulrich 2015 126 65 14 26 0.90 [ 0.84, 0.94 ] 0.29 [ 0.20, 0.39 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 6. Dermoscopy observer diagnosis (BCC).
Review: Optical coherence tomography for diagnosing skin cancer in adults
Test: 6 Dermoscopy observer diagnosis (BCC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Markowitz 2015 55 20 15 25 0.79 [ 0.67, 0.87 ] 0.56 [ 0.40, 0.70 ]
Ulrich 2015 126 42 13 50 0.91 [ 0.85, 0.95 ] 0.54 [ 0.44, 0.65 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 7. OCT Berlin score ≥ 8 (BCC).
Review: Optical coherence tomography for diagnosing skin cancer in adults
Test: 7 OCT Berlin score≥ 8 (BCC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wahrlich 2015 28 5 1 16 0.97 [ 0.82, 1.00 ] 0.76 [ 0.53, 0.92 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 8. OCT Berlin score ≥ 12 (BCC).
Review: Optical coherence tomography for diagnosing skin cancer in adults
Test: 8 OCT Berlin score≥ 12 (BCC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wahrlich 2015 19 3 10 18 0.66 [ 0.46, 0.82 ] 0.86 [ 0.64, 0.97 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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Test 9. OCT Berlin score ≥ 8 (cutaneous squamous cell carcinoma (cSCC)).
Review: Optical coherence tomography for diagnosing skin cancer in adults
Test: 9 OCT Berlin score≥ 8 (cutaneous squamous cell carcinoma (cSCC))
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wahrlich 2015 5 0 4 41 0.56 [ 0.21, 0.86 ] 1.00 [ 0.91, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
Test 10. OCT Berlin score ≥ 12 (cSCC).
Review: Optical coherence tomography for diagnosing skin cancer in adults
Test: 10 OCT Berlin score≥ 12 (cSCC)
Study TP FP FN TN Sensitivity Specificity Sensitivity Specificity
Wahrlich 2015 3 0 6 41 0.33 [ 0.07, 0.70 ] 1.00 [ 0.91, 1.00 ]
0 0.2 0.4 0.6 0.8 1 0 0.2 0.4 0.6 0.8 1
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A D D I T I O N A L T A B L E S
Table 1. Glossary of terms
Term Definition
Acantholytic subtypes An uncommon squamous cell carcinoma variant characterised by acanthol-
ysis, which is the marked disruption of intercellular connections and result-
ing separation of epidermal cells
Arborising blood vessels Blood vessels in the skin that form a tree-like branching appearance. They
can be a sign of basal cell carcinomas
Atypical honeycombing This pattern arises from variation in size and shape of keratinocytic nuclei
and irregular cell borders of keratinocytes in the spinous-granular epidermal
layer. It is a feature of actinic keratosis and squamous cell carcinoma on
optical coherence tomography and on reflective confocal microscopy exam-
ination
Atypical intraepidermal melanocytic variant Unusual area of darker pigmentation contained within the epidermis that
may progress to an invasive melanoma; includes melanoma in situ and
lentigo maligna
Atypical naevi Unusual looking but non-cancerous mole or area of darker pigmentation
of the skin
Atypical pleomorphic keratinocytes Abnormal skin cells of different shapes and sizes, a feature visible on
histopathology
Axial resolution Axial resolution describes the ability of an optical coherence tomography
system to distinguish between 2 points in space that lie in the direction
parallel to the light beam
Basaloid cells Cells in the skin that look like those in epidermal basal layer
BRAF inhibitors Therapeutic agentswhich inhibit the serine-threonine protein kinase BRAF-
mutated metastatic melanoma
BRAF V600 mutation BRAF is a human gene that makes a protein called B-Raf which is involved
in the control of cell growth. BRAF mutations (damaged DNA) occur in
around 40% of melanomas, which can then be treated with particular drugs
Breslow thickness A scale for measuring the thickness of melanomas by the pathologist using
a microscope, measured in millimetres from the top layer of skin to the
bottom of the tumour
Congenital naevi A type of mole found on infants at birth
Dermal nests Collections of pigment cells that are bunched together in the dermis
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Table 1. Glossary of terms (Continued)
Dermal papilla Small projections of the dermis into the overlying epidermis giving an un-
dulating pattern and visible as ’fingerprints’ in hands and feet
Dermoepidermal junction The area where the lower part of the epidermis and top layer of the dermis
meet
Dermoscopy Whereby a hand-held microscope is used to allow more detailed, magnified
examination of the skin compared to examination by the naked eye alone
Dermis Layer of skin below the epidermis, composed of living tissue and contain-
ing blood capillaries, nerve endings, sweat glands, hair follicles, and other
structures
Desmoplastic subtypes of squamous cell carcinoma An aggressive squamous cell carcinoma variant characterised by a prolifer-
ation of fibroblasts and formation of fibrous connective tissue
Electrodessication The use of high-frequency electric currents to cut, destroy, or cauterise tissue.
It is performed using a fine needle-shaped instrument
Epidermis Outer layer of the skin
False negative A person who is truly positive for a disease, but whom a diagnostic test
classifies them as disease-free
False positive A person who is truly disease-free, but whom a diagnostic test classifies them
as having the disease
Fibrotic septa Excess fibrous connective tissue formation separating other parts of tissue
Grey-blue ovoid nests and globules Grey-blue coloured oval shaped areas seen under dermoscopy that may
represent basal cell carcinomas
Histopathology/histology The study of tissue, usually obtained by biopsy or excision, for example
under a microscope
Horizontal signal intense cords Thick hyperechogenic lines that form a mesh like network, orientated hor-
izontally, with hypoechogenic areas within it
Hyperechogenic An area of brightness on an OCT scan representing an increased response
of tissue during imaging
Hypertrophic actinic keratosis Precancerous scaly patches of skin that are particularly thickened
Hypoechogenic Displaying lower echogenicity reflecting and appears darker on ultrasonog-
raphy
Incidence The number of new cases of a disease in a given time period
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Table 1. Glossary of terms (Continued)
Index test A diagnostic test under evaluation in a primary study
Inflammatory dermatoses Skin conditions where the main disease process is inflammatory, often in-
volving immune cells, as opposed to malignant or infectious processes. The
inflammatory process may be due to internal or external factors
Interferometry The measurement of waves of light or sound after interference in order to
extract information
Interfollicular epidermis The part of the epidermis that lies in between the hair follicles
Junctional nests Collections of pigment cells bunched up around the junction between the
epidermis and dermis
Lateral resolution Describes the ability of an optical coherence tomography system to distin-
guish between 2 points in space that lie in a perpendicular direction to the
light beam
Lentigo maligna Unusual area of darker pigmentation contained within the epidermis which
includes malignant cells but with no invasive growth. May progress to an
invasive melanoma
Lymph node Lymph nodes filter the lymphatic fluid (clear fluid containing white blood
cells) that travels around the body to help fight disease; they are located
throughout the body often in clusters (nodal basins)
Melanocytic naevus An area of skin with darker pigmentation (or melanocytes) also referred to
as ’moles’
Meta-analysis A form of statistical analysis used to synthesise results from a collection of
individual studies
Metastases/metastatic disease Spread of cancer away from the primary site to somewhere else through the
bloodstream or the lymphatic system
Micrometastases Micrometastases are metastases so small that they can only be seen under a
microscope
Mitotic activity Relates to the presence of proliferating cells and used as an index of tumour
aggressiveness
Mitotic rate Microscopic evaluation of number of cells actively dividing in a tumour
Morbidity Detrimental effects on health
Mortality Either 1. the condition of being subject to death; or 2. the death rate, which
reflects the number of deaths per unit of population in relation to any
specific region, age group, disease, treatment, or other classification, usually
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Table 1. Glossary of terms (Continued)
expressed as deaths per 100, 1000, 10,000, or 100,000 people
Multi-disciplinary team A team with members from different healthcare professions and specialities
(e.g. urology, oncology, pathology, radiology, and nursing). Cancer care
in the National Health Service (NHS) uses this system to ensure that all
relevant health professionals are engaged to discuss the best possible care for
that patient
Naevus A mole or collection of pigment cells (plural: naevi or nevi)
Nuclear dysplasia and mitoses Ahistopathological term referring to abnormal nucleiwith increasedmitotic
activity and nuclear size associated with disordered nuclear dysplasia and
mitoses cell growth
Nucleated Presence of a nuclei within a cell, which contain most of the cell’s genetic
material
Pagetoid cells Abnormal pigment cells that spread upwards through the epidermis
Papillary dermis Also called the ’upper dermis,’ this is the uppermost layer of the dermis that
connects to the dermal-epidermal junction
Peripheral palisading Ahistopathological term referring to the wall-like appearance of cells around
a central focus
Pleomorphic Variability in size or shape
Polygonal cells Skin cells that appear to have many sides, such as taking up a pentagonal,
hexagonal, or octagonal appearance
Prevalence Proportion of a population found to have a condition.
Prognostic factors/indicators Specific characteristics of a cancer or the person who has it which might
affect the patient’s prognosis
Receiver operating characteristic (ROC) plot A plot of the sensitivity and 1 minus the specificity of a test at the different
possible thresholds for test positivity; represents the diagnostic capability of
a test with a range of binary test results
ROC analysis The analysis of an ROC plot of a test to select an optimal threshold for test
positivity
Recurrence Recurrence is when new cancer cells are detected following treatment. This
can occur either at the site of the original tumour or at other sites in the
body
Reference Standard A test or combination of tests used to establish the final or ’true’ diagnosis
of a patient in an evaluation of a diagnostic test
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Table 1. Glossary of terms (Continued)
Reflectance confocal microscopy (RCM) A microscopic technique using infrared light (either in a hand-held device
or a static unit) that can create images of the deeper layers of the skin
Resolution Resolution in an imaging system refers to its ability to distinguish 2 points
in space as being separate points; resolution is measured in 2 directions:
axial and lateral
Rete ridges Also called ’epidermal ridges’ or ’epidermal pegs,’ they represent downward
projections of the epidermis into underlying connective tissue
Reticular dermis Also called the ’lower dermis,’ the reticular dermis is the lower layer of the
dermis, located under the papillary dermis
Sensitivity In this context the term is used to mean the proportion of people with a
disease who have that disease correctly identified by the study test
Specificity The proportion of people without the disease of interest (in this case with
benign skin lesions) who have that absence of disease correctly identified by
the study test
Spectroscopy Study of the interaction between matter and electromagnetic radiation
Spindle subtypes of SCC A squamous cell carcinoma variant characterised by poorly differentiated
spindle cells surrounded by collagenous stroma
Spinous-granular layer 1 of several layers of the epidermis, which is the outermost layer of skin. The
nuclei of keratinocytes, which contain most of the cell’s genetic material are
found here
Staging Clinical description of the size and spread of a person’s tumour, fitting into
internationally agreed categories
Stratum corneum The outermost layer of the epidermis. This layer is the most superficial layer
of skin, which is composed of flattened skin cells organised like a brick wall.
In normal conditions cells are not nucleated at this layer
Stromal reaction Change in connective tissue microenvironment
Subclinical (disease) Disease that is usually asymptomatic and not easily observable, e.g. by clin-
ical or physical examination
Superficial fine telangiectasia Fine dilated blood vessels of small/varying diameter located in the superficial
dermis
Targetoid hair follicles The presence of yellow keratotic follicular plugs surrounded by a white rim
on dermoscopy, more frequently known as ’white circle,’ which can be a
characteristic of squamous cell carcinoma
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Table 2. Description of diagnostic thresholds used by optical coherence tomography for the detection of all target conditions
Study Threshold Threshold detail
Melanoma
Gambichler 2014
HD-OCT
Score ≥ -1 MM; score of ≥ -1.5 benign MSL,
based on sum of subscores for various OCT char-
acteristics
New scoring system based on previously de-
scribedmicromorphological HD-OCT correlates
of melanocytic skin lesions (Boone 2014; Picard
2013) and from RCM (Segura 2009) and con-
ventionalOCT studies (Gambichler 2007).OCT
scoring based on “predominant presence of the
following risk (+) or protective (-) (or both) fea-
tures … (i) HD-OCT en-face mode - typical
basal cells/clusters (-1), edged papillae (-1), hon-
eycomb/cobblestone pattern (-1), large roundish
pagetoid cells (+1), atypical cell clusters in the der-
moepidermal junction (DEJ) (+1), totally disar-
ranged epidermal/ dermal pattern (+1); (ii) HD-
OCT slice mode - clearly demarcated DEJ (-
0.5), finger-shaped elongated rete ridges (-0.5),
bright bizarre dermal horizontal streaks (+0.5),
large vertical icicle-shaped structures (+0.5). The
total score is the sum of the aforementioned sub-
scores for the various particular criteria.”
Wessels 2015
SS-OCT
Attenuation coefficient 5.4 mm ¹ Based on 2D scans: “The attenuation coefficient
is the decrease in light intensity per millimetre;
measurement was performed as described before
(Faber 2004) using custom written software (Lab-
VIEW 2011; National Instruments, Austin, TX,
USA).” The optimal attenuation coefficient of 5.
4 mm ¹ was estimated using Youden’s index
(Attenuation refers to the loss of signal by scatter-
ing and absorption of light; scattering is caused
by the nature of cellular structures, while absorp-
tion is caused by skin tissue’s biochemical compo-
sition. The ’attenuation coefficient (µoct)’ plots
OCT signal decay by its penetration depth. The
authors hypothesised that this tracks morpholog-
ical and physiological changes in tissue.)
Study also investigated accuracy of 2 morpholog-
ical features on 3D scans (absence of clear DEJ
and no lower boundary of lesion visible) but these
were excluded from review
BCC
Markowitz 2015
SS-OCT
Diagnostic judgement (BCC present/absent) Observer diagnosis was based on features de-
scribed in previous studies (Maier 2013; Ulrich
2015; Wahrlich 2015): “epidermis was analysed
for protrusions into the dermis with shadowing;
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Table 2. Description of diagnostic thresholds used by optical coherence tomography for the detection of all target conditions
(Continued)
the epidermal-dermal junction for lack of defi-
nition or rupturing; and the dermis for signal-
poor ovoid structures, dark rims, ovoid structures
with bright centres, dilated vessels, black areas or
cysts, bright stroma, and/or small ovoid signal-
poor structures (’fish shoal’).”
Ulrich 2015
SS-OCT
Diagnostic judgement (BCC present/absent) Observer diagnosis; based on “Epidermis: protru-
sions into the dermis with shadowing; dermoepi-
dermal junction: lack of definition or rupturing;
and dermis: signal-poor ovoid structures, dark
rims, ovoid structures with bright centres, dilated
vessels, black areas or cysts, bright stroma and
small ovoid signal-poor structures (’fish shoal’).
” Paper cited Boone 2012’s identification of fea-
tures for BCC as having been published since the
study was designed
Wahrlich 2015
SS-OCT
1. Berlin score ≥ 8
2. Berlin score ≥ 12
BCC features subdivided into major (dark bor-
ders underneath the tumour, hyporeflective nests,
and ovoid structures) and minor criteria (disrup-
tion of DEJ and cysts). The presence of each fea-
ture was classed between 0 (absent) and 3 (clearly
recognisable structure); visible (2) and less visi-
ble (1) structures could not clearly be allocated.
Criteria were added to a cumulative score with
a maximum of 24 points. Binary logistic regres-
sion identified limit values (T1, T2) to differen-
tiate BCC from ’others’ using lesions in phase
1 of the study (100 BCC and 30 ’other’ skin
diseases; using student observers). T1 threshold
identified as ≥ 8 and T2 ≥ 12. Main diagnostic
features were based on already existing data from
other study groups (Khandwala 2010; Mogensen
2009a; Sabban 2004; Vogt 2003; Zhao 2008).
2D: two dimensional; 3D: three-dimensional; BCC: basal cell carcinoma; DEJ: dermoepidermal junction; HD-OCT: high-definition
optical coherence tomography; MM: malignant melanoma; MSL: melanocytic skin lesion; OCT: optical coherence tomography;
RCM: reflectance confocal microscopy; SS-OCT: swept-source optical coherence tomography.
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A P P E N D I C E S
Appendix 1. Current content and structure of the Programme Grant
LIST OF REVIEWS Number of studies
Diagnosis of melanoma
1 Visual inspection 49
2 Dermoscopy +/- visual inspection 104
3 Teledermatology 22
4 Smartphone applications 2
5a Computer-assisted diagnosis - dermoscopy-based techniques 42
5b Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
6 Reflectance confocal microscopy 18
7 High-frequency ultrasound 5
Diagnosis of keratinocyte skin cancer (BCC and cSCC)
8 Visual inspection +/- Dermoscopy 24
5c Computer-assisted diagnosis - dermoscopy-based techniques Review amalgamated into 5a
5d Computer-assisted diagnosis - spectroscopy-based techniques Review amalgamated into 5a
9 Optical coherence tomography 5
10 Reflectance confocal microscopy 10
11 Exfoliative cytology 9
Staging of melanoma
12 Imaging tests (ultrasound, CT, MRI, PET-CT) 38
13 Sentinel lymph node biopsy 160
Staging of cSCC
Imaging tests review Review dropped; only one study identified
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(Continued)
13 Sentinel lymph node biopsy Review amalgamated into 13 above (n = 15 studies)
Appendix 2. Final search strategies
Melanoma search strategies to August 2016
Database: Ovid MEDLINE(R) 1946 to August week 3 2016
Search strategy:
1 exp melanoma/
2 exp skin cancer/
3 exp basal cell carcinoma/
4 basalioma$1.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or CSCC or NMSC).ti,ab.
11 keratinocy$.ti,ab.
12 Keratinocytes/
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 exp epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 exp diagnosis, computer-assisted/
38 MoleMax.ti,ab.
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
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41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 Aura.ti,ab.
44 (optical adj2 scan$).ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 (high adj3 ultraso$).ti,ab.
51 (canine adj2 detect$).ti,ab.
52 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
53 smartphone$.ti,ab.
54 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
55 Mole Detective.ti,ab.
56 Spot Check.ti,ab.
57 (mole$1 adj2 map$).ti,ab.
58 (total adj2 body).ti,ab.
59 exfoliative cytolog$.ti,ab.
60 digital analys$.ti,ab.
61 (image$1 adj3 software).ti,ab.
62 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (computer adj2 diagnos$).ti,ab.
65 exp sentinel lymph node biopsy/
66 (sentinel adj2 node).ti,ab.
67 nevisense.mp. or HFUS.ti,ab.
68 electrical impedance spectroscopy.ti,ab.
69 history taking.ti,ab.
70 patient history.ti,ab.
71 (naked eye adj (exam$ or assess$)).ti,ab.
72 (skin adj exam$).ti,ab.
73 physical examination/
74 ugly duckling.mp. or UD.ti,ab.
75 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
76 ABCDE.mp. or VOC.ti,ab.
77 clinical accuracy.ti,ab.
78 Family Practice/ or Physicians, Family/ or clinical competence/
79 (confocal adj2 microscop$).ti,ab.
80 diagnostic algorithm$1.ti,ab.
81 checklist$.ti,ab.
82 virtual imag$1.ti,ab.
83 volatile organic compound$1.ti,ab.
84 dog$1.ti,ab.
85 gene expression analy$.ti,ab.
86 reflex transmission imag$.ti,ab.
87 thermal imaging.ti,ab.
88 elastography.ti,ab.
89 or/14-88
90 (CT or PET).ti,ab.
91 PET-CT.ti,ab.
92 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
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93 exp Deoxyglucose/
94 deoxy-glucose.ti,ab.
95 deoxyglucose.ti,ab.
96 CATSCAN.ti,ab.
97 exp Tomography, Emission-Computed/
98 exp Tomography, X-ray computed/
99 positron emission tomograph$.ti,ab.
100 exp magnetic resonance imaging/
101 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
102 exp echography/
103 Doppler echography.ti,ab.
104 sonograph$.ti,ab.
105 ultraso$.ti,ab.
106 doppler.ti,ab.
107 magnetic resonance imag$.ti,ab.
108 or/90-107
109 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
110 “Sensitivity and Specificity”/
111 exp cancer staging/
112 or/109-111
113 108 and 112
114 89 or 113
115 13 and 114
Database: Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations 29 August 2016
Search strategy:
1 basalioma$1.ti,ab.
2 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or lesion$1 or malignan$ or nodule$1)).ti,ab.
3 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
4 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
5 nmsc.ti,ab.
6 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or masses or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or
epithelioma$1 or epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
7 (BCC or CSCC or NMSC).ti,ab.
8 keratinocy$.ti,ab.
9 or/1-8
10 dermoscop$.ti,ab.
11 dermatoscop$.ti,ab.
12 photomicrograph$.ti,ab.
13 (epiluminescence adj2 microscop$).ti,ab.
14 (confocal adj2 microscop$).ti,ab.
15 (incident light adj2 microscop$).ti,ab.
16 (surface adj2 microscop$).ti,ab.
17 (visual adj (inspect$ or examin$)).ti,ab.
18 ((clinical or physical) adj examin$).ti,ab.
19 3 point.ti,ab.
20 three point.ti,ab.
21 pattern analys$.ti,ab.
22 ABCD$.ti,ab.
23 menzies.ti,ab.
24 7 point.ti,ab.
25 seven point.ti,ab.
26 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
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27 artificial intelligence.ti,ab.
28 AI.ti,ab.
29 computer assisted.ti,ab.
30 computer aided.ti,ab.
31 neural network$.ti,ab.
32 MoleMax.ti,ab.
33 image process$.ti,ab.
34 automatic classif$.ti,ab.
35 image analysis.ti,ab.
36 SIAscop$.ti,ab.
37 Aura.ti,ab.
38 (optical adj2 scan$).ti,ab.
39 MelaFind.ti,ab.
40 SIMSYS.ti,ab.
41 MoleMate.ti,ab.
42 SolarScan.ti,ab.
43 VivaScope.ti,ab.
44 (high adj3 ultraso$).ti,ab.
45 (canine adj2 detect$).ti,ab.
46 ((mobile or cell or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
47 smartphone$.ti,ab.
48 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
49 Mole Detective.ti,ab.
50 Spot Check.ti,ab.
51 (mole$1 adj2 map$).ti,ab.
52 (total adj2 body).ti,ab.
53 exfoliative cytolog$.ti,ab.
54 digital analys$.ti,ab.
55 (image$1 adj3 software).ti,ab.
56 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$ or tele-
dermatoscop$).ti,ab.
57 (optical coherence adj (technolog$ or tomog$)).ti,ab.
58 (computer adj2 diagnos$).ti,ab.
59 (sentinel adj2 node).ti,ab.
60 nevisense.mp. or HFUS.ti,ab.
61 electrical impedance spectroscopy.ti,ab.
62 history taking.ti,ab.
63 patient history.ti,ab.
64 (naked eye adj (exam$ or assess$)).ti,ab.
65 (skin adj exam$).ti,ab.
66 ugly duckling.mp. or UD.ti,ab.
67 ((physician$ or clinical or physical) adj (exam$ or triage or recog$)).ti,ab.
68 ABCDE.mp. or VOC.ti,ab.
69 clinical accuracy.ti,ab.
70 (Family adj (Practice or Physicians)).ti,ab.
71 (confocal adj2 microscop$).ti,ab.
72 clinical competence.ti,ab.
73 diagnostic algorithm$1.ti,ab.
74 checklist$.ti,ab.
75 virtual imag$1.ti,ab.
76 volatile organic compound$1.ti,ab.
77 dog$1.ti,ab.
78 gene expression analy$.ti,ab.
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79 reflex transmission imag$.ti,ab.
80 thermal imaging.ti,ab.
81 elastography.ti,ab.
82 or/10-81
83 (CT or PET).ti,ab.
84 PET-CT.ti,ab.
85 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
86 deoxy-glucose.ti,ab.
87 deoxyglucose.ti,ab.
88 CATSCAN.ti,ab.
89 positron emission tomograph$.ti,ab.
90 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
91 Doppler echography.ti,ab.
92 sonograph$.ti,ab.
93 ultraso$.ti,ab.
94 doppler.ti,ab.
95 magnetic resonance imag$.ti,ab.
96 or/83-95
97 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
98 96 and 97
99 82 or 98
100 9 and 99
Database: Embase 1974 to 29 August 2016
Search strategy:
1 *melanoma/
2 *skin cancer/
3 *basal cell carcinoma/
4 basalioma$.ti,ab.
5 ((basal cell or skin) adj2 (cancer$1 or carcinoma$1 or mass or masses or tumour$1 or tumor$1 or neoplasm$ or adenoma$ or
epithelioma$ or lesion$ or malignan$ or nodule$)).ti,ab.
6 (pigmented adj2 (lesion$1 or mole$ or nevus or nevi or naevus or naevi or skin)).ti,ab.
7 (melanom$1 or nonmelanoma$1 or non-melanoma$1 or melanocyt$ or non-melanocyt$ or nonmelanocyt$ or keratinocyt$).ti,ab.
8 nmsc.ti,ab.
9 (squamous cell adj2 (cancer$1 or carcinoma$1 or mass or tumor$1 or tumour$1 or neoplasm$1 or adenoma$1 or epithelioma$1 or
epithelial or lesion$1 or malignan$ or nodule$1) adj2 (skin or epiderm$ or cutaneous)).ti,ab.
10 (BCC or cscc).mp. or NMSC.ti,ab.
11 keratinocyte.ti,ab.
12 keratinocy$.ti,ab.
13 or/1-12
14 dermoscop$.ti,ab.
15 dermatoscop$.ti,ab.
16 photomicrograph$.ti,ab.
17 *epiluminescence microscopy/
18 (epiluminescence adj2 microscop$).ti,ab.
19 (confocal adj2 microscop$).ti,ab.
20 (incident light adj2 microscop$).ti,ab.
21 (surface adj2 microscop$).ti,ab.
22 (visual adj (inspect$ or examin$)).ti,ab.
23 ((clinical or physical) adj examin$).ti,ab.
24 3 point.ti,ab.
25 three point.ti,ab.
26 pattern analys$.ti,ab.
27 ABCD$.ti,ab.
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28 menzies.ti,ab.
29 7 point.ti,ab.
30 seven point.ti,ab.
31 (digital adj2 (dermoscop$ or dermatoscop$)).ti,ab.
32 artificial intelligence.ti,ab.
33 AI.ti,ab.
34 computer assisted.ti,ab.
35 computer aided.ti,ab.
36 neural network$.ti,ab.
37 MoleMax.ti,ab.
38 exp diagnosis, computer-assisted/
39 image process$.ti,ab.
40 automatic classif$.ti,ab.
41 image analysis.ti,ab.
42 SIAscop$.ti,ab.
43 (optical adj2 scan$).ti,ab.
44 Aura.ti,ab.
45 MelaFind.ti,ab.
46 SIMSYS.ti,ab.
47 MoleMate.ti,ab.
48 SolarScan.ti,ab.
49 VivaScope.ti,ab.
50 confocal microscop$.ti,ab.
51 (high adj3 ultraso$).ti,ab.
52 (canine adj2 detect$).ti,ab.
53 ((mobile or cell$ or cellular or smart) adj ((phone$1 adj2 app$1) or application$1)).ti,ab.
54 smartphone$.ti,ab.
55 (DermoScan or SkinVision or DermLink or SpotCheck).ti,ab.
56 Spot Check.ti,ab.
57 Mole Detective.ti,ab.
58 (mole$1 adj2 map$).ti,ab.
59 (total adj2 body).ti,ab.
60 exfoliative cytolog$.ti,ab.
61 digital analys$.ti,ab.
62 (image$1 adj3 software).ti,ab.
63 (optical coherence adj (technolog$ or tomog$)).ti,ab.
64 (teledermatolog$ or tele-dermatolog$ or telederm or tele-derm or teledermoscop$ or tele-dermoscop$ or teledermatoscop$).mp. or
tele-dermatoscop$.ti,ab.
65 (computer adj2 diagnos$).ti,ab.
66 *sentinel lymph node biopsy/
67 (sentinel adj2 node).ti,ab.
68 nevisense.ti,ab.
69 HFUS.ti,ab.
70 electrical impedance spectroscopy.ti,ab.
71 history taking.ti,ab.
72 patient history.ti,ab.
73 (naked eye adj (exam$ or assess$)).ti,ab.
74 (skin adj exam$).ti,ab.
75 *physical examination/
76 ugly duckling.ti,ab.
77 UD sign$.ti,ab.
78 ((physician$ or clinical or physical) adj (exam$ or recog$ or triage)).ti,ab.
79 ABCDE.ti,ab.
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80 clinical accuracy.ti,ab.
81 *general practice/
82 (confocal adj2 microscop$).ti,ab.
83 clinical competence/
84 diagnostic algorithm$.ti,ab.
85 checklist$1.ti,ab.
86 virtual image$1.ti,ab.
87 volatile organic compound$1.ti,ab.
88 VOC.ti,ab.
89 dog$1.ti,ab.
90 gene expression analys$.ti,ab.
91 reflex transmission imaging.ti,ab.
92 thermal imaging.ti,ab.
93 elastography.ti,ab.
94 dog$1.ti,ab.
95 gene expression analys$.ti,ab.
96 reflex transmission imaging.ti,ab.
97 thermal imaging.ti,ab.
98 elastography.ti,ab.
99 or/14-93
100 PET-CT.ti,ab.
101 (CT or PET).ti,ab.
102 (FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical$).ti,ab.
103 exp Deoxyglucose/
104 CATSCAN.ti,ab.
105 deoxyglucose.ti,ab.
106 deoxy-glucose.ti,ab.
107 *positron emission tomography/
108 *computer assisted tomography/
109 positron emission tomograph$.ti,ab.
110 *nuclear magnetic resonance imaging/
111 (MRI or fMRI or NMRI or scintigraph$).ti,ab.
112 *echography/
113 Doppler.ti,ab.
114 sonograph$.ti,ab.
115 ultraso$.ti,ab.
116 magnetic resonance imag$.ti,ab.
117 or/100-116
118 (stage$ or staging or metasta$ or recurrence or sensitivity or specificity or false negative$ or thickness$).ti,ab.
119 “Sensitivity and Specificity”/
120 *cancer staging/
121 or/118-120
122 117 and 121
123 99 or 122
124 13 and 123
Database: Cochrane Library (Wiley) 2016 searched 30 August 2016 CDSR Issue 8 of 12 2016 CENTRAL Issue 7 of 12 2016
HTA Issue 3 of 4 July 2016 DARE Issue 3 of 4 2015
Search strategy:
#1 melanoma* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyte*
#2 MeSH descriptor: [Melanoma] explode all trees
#3 “skin cancer*”
#4 MeSH descriptor: [Skin Neoplasms] explode all trees
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#5 skin near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*)
#6 nmsc
#7 “squamous cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma*
or lesion* or malignan* or nodule*) near/2 (skin or epiderm* or cutaneous)
#8 “basal cell” near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
#9 pigmented near/2 (lesion* or nevus or mole* or naevi or naevus or nevi or skin)
#10 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9
#11 dermoscop*
#12 dermatoscop*
#13 Photomicrograph*
#14 MeSH descriptor: [Dermoscopy] explode all trees
#15 confocal near/2 microscop*
#16 epiluminescence near/2 microscop*
#17 incident next light near/2 microscop*
#18 surface near/2 microscop*
#19 “visual inspect*”
#20 “visual exam*”
#21 (clinical or physical) next (exam*)
#22 “3 point”
#23 “three point”
#24 “pattern analys*”
#25 ABDC
#26 menzies
#27 “7 point”
#28 “seven point”
#29 digital near/2 (dermoscop* or dermatoscop*)
#30 “artificial intelligence”
#31 “AI”
#32 “computer assisted”
#33 “computer aided”
#34 AI
#35 “neural network*”
#36 MoleMax
#37 “computer diagnosis”
#38 “image process*”
#39 “automatic classif*”
#40 SIAscope
#41 “image analysis”
#42 “optical near/2 scan*”
#43 Aura
#44 MelaFind
#45 SIMSYS
#46 MoleMate
#47 SolarScan
#48 Vivascope
#49 “confocal microscopy”
#50 high near/3 ultraso*
#51 canine near/2 detect*
#52 Mole* near/2 map*
#53 total near/2 body
#54 mobile* or smart near/2 phone*
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#55 cell next phone*
#56 smartphone*
#57 “mitotic index”
#58 DermoScan or SkinVision or DermLink or SpotCheck
#59 “Mole Detective”
#60 “Spot Check”
#61 mole* near/2 map*
#62 total near/2 body
#63 “exfoliative cytolog*”
#64 “digital analys*”
#65 image near/3 software
#66 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatolog*
#67 “optical coherence” next (technolog* or tomog*)
#68 computer near/2 diagnos*
#69 sentinel near/2 node*
#70 #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28
or #29 or #30 or #31 or #32 or #33 or #34 or #35 or #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 or #46 or
#47 or #48 or #49 or #50 or #51 or #52 or #53 or #54 or #55 or #56 or #57 or #58 or #59 or #60 or #61 or #62 or #63 or #64 or #
65 or #66 or #67 or #68 or #69
#71 ultraso*
#72 sonograph*
#73 MeSH descriptor: [Ultrasonography] explode all trees
#74 Doppler
#75 CT or PET or PET-CT
#76 “CAT SCAN” or “CATSCAN”
#77 MeSH descriptor: [Positron-Emission Tomography] explode all trees
#78 MeSH descriptor: [Tomography, X-Ray Computed] explode all trees
#79 MRI
#80 MeSH descriptor: [Magnetic Resonance Imaging] explode all trees
#81 MRI or fMRI or NMRI or scintigraph*
#82 “magnetic resonance imag*”
#83 MeSH descriptor: [Deoxyglucose] explode all trees
#84 deoxyglucose or deoxy-glucose
#85 “positron emission tomograph*”
#86 #71 or #72 or #73 or #74 or #75 or #76 or #77 or #78 or #79 or #80 or #81 or #82 or #83 or #84 or #85
#87 stage* or staging or metasta* or recurrence or sensitivity or specificity or “false negative*” or thickness*
#88 MeSH descriptor: [Neoplasm Staging] explode all trees
#89 #87 or #88
#90 #89 and #86
#91 #70 or #90
#92 #10 and #91
#93 BCC or CSCC or NMCS
#94 keratinocy*
#95 #93 or #94
#96 #10 or #95
#97 nevisense
#98 HFUS
#99 “electrical impedance spectroscopy”
#100 “history taking”
#101 “patient history”
#102 naked next eye near/1 (exam* or assess*)
#103 skin next exam*
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#104 “ugly duckling” or (UD sign*)
#105 MeSH descriptor: [Physical Examination] explode all trees
#106 (physician* or clinical or physical) near/1 (exam* or recog* or triage*)
#107 ABCDE
#108 “clinical accuracy”
#109 MeSH descriptor: [General Practice] explode all trees
#110 confocal near microscop*
#111 “diagnostic algorithm*”
#112 MeSH descriptor: [Clinical Competence] explode all trees
#113 checklist*
#114 “virtual image*”
#115 “volatile organic compound*”
#116 dog or dogs
#117 VOC
#118 “gene expression analys*”
#119 “reflex transmission imaging”
#120 “thermal imaging”
#121 elastography
#122 #97 or #98 or #99 or #100 or #101 or #102 or #103 or #104 or #105 or #106 or #107 or #108 or #109 or #110 or #111 or #
112 or #113 or #114 or #115 or #116 or #117 or #118 or #119 or #120 or #121
#123 #70 or #122
#124 #96 and #123
#125 #96 and #90
#126 #125 or #124
#127 #10 and #126
Database : CINAHL Plus (EBSCO) 1937 to 30 August 2016
Search strategy:
S1 (MH “Melanoma”) OR (MH “Nevi and Melanomas+”)
S2 (MH “Skin Neoplasms+”)
S3 (MH “Carcinoma, Basal Cell+”)
S4 basalioma*
S5 (basal cell) N2 (cancer* or carcinoma* or mass or masses or tumor* or tumour* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*)
S6 (pigmented) N2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin)
S7 melanom* or nonmelanoma* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt*
S8 nmsc
S9 TX BCC or cscc or NMSC
S10 (MH “Keratinocytes”)
S11 keratinocyt*
S12 S1 OR S2 OR S3 OR S4 OR S5 OR S6 OR S7 OR S8 OR S9 OR S10 OR S11
S13 dermoscop* or dermatoscop* or photomicrograph* or (3 point) or (three point) or ABCD* or menzies or (7 point) or (seven
point) or AI or Molemax or SIASCOP* or Aura or MelaFind or SIMSYS or MoleMate or SolarScan or smartphone* or DermoScan
or SkinVision or DermLink or SpotCheck
S14 (epiluminescence or confocal or incident or surface) N2 (microscop*)
S15 visual N1 (inspect* or examin*)
S16 (clinical or physical) N1 (examin*)
S17 pattern analys*
S18 (digital) N2 (dermoscop* or dermatoscop*)
S19 (artificial intelligence)
S20 (computer) N2 (assisted or aided)
S21 (neural network*)
S22 (MH “Diagnosis, Computer Assisted+”)
S23 (image process*)
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S24 (automatic classif*)
S25 (image analysis)
S26 SIAScop*
S27 (optical) N2 (scan*)
S28 (high) N3 (ultraso*)
S29 elastography
S30 (mobile or cell or cellular or smart) N2 (phone*) N2 (app or application*)
S31 (mole*) N2 (map*)
S32 total N2 body
S33 exfoliative cytolog*
S34 digital analys*
S35 image N3 software
S36 teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop* or tele-dermoscop* or teledermatoscop* or tele-
dermatoscop* teledermatolog* or tele-dermatolog* or telederm or tele-derm or teledermoscop*
S37 (optical coherence) N1 (technolog* or tomog*)
S38 computer N2 diagnos*
S39 sentinel N2 node
S40 (MH “Sentinel Lymph Node Biopsy”)
S41 nevisense or HFUS or checklist* or VOC or dog*
S42 electrical impedance spectroscopy
S43 history taking
S44 “Patient history”
S45 naked eye
S46 skin exam*
S47 physical exam*
S48 ugly duckling
S49 UD sign*
S50 (physician* or clinical or physical) N1 (exam*)
S51 clinical accuracy
S52 general practice
S53 (physician* or clinical or physical) N1 (recog* or triage)
S54 confocal microscop*
S55 clinical competence
S56 diagnostic algorithm*
S57 checklist*
S58 virtual image*
S59 volatile organic compound*
S60 gene expression analys*
S61 reflex transmission imag*
S62 thermal imaging
S63 S13 or S14 or S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 OR
S28 OR S29 OR S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42 OR
S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50 OR S51 OR S52 OR S53 OR S54 OR S55 OR S56 OR S57 OR
S58 OR S59 OR S60 OR S61 OR S62
S64 CT or PET
S65 PET-CT
S66 FDG or F18 or Fluorodeoxyglucose or radiopharmaceutical*
S67 (MH “Deoxyglucose+”)
S68 deoxy-glucose or deoxyglucose
S69 CATSCAN
S70 CAT-SCAN
S71 (MH “Deoxyglucose+”)
S72 (MH “Tomography, Emission-Computed+”)
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S73 (MH “Tomography, X-Ray Computed”)
S74 positron emission tomograph*
S75 (MH “Magnetic Resonance Imaging+”)
S76 MRI or fMRI or NMRI or scintigraph*
S77 echography
S78 doppler
S79 sonograph*
S80 ultraso*
S81 magnetic resonance imag*
S82 S64 OR S65 OR S66 OR S67 OR S68 OR S69 OR S70 OR S71 OR S72 OR S73 OR S74 OR S75 OR S76 OR S77 OR S78
OR S79 OR S80 OR S81
S83 stage* or staging or metasta* or recurrence or sensitivity or specificity or (false negative*) or thickness
S84 (MH “Neoplasm Staging”)
S85 S83 OR S84
S86 S82 AND S85
S87 S63 OR S86
S88 S12 AND S87
Database: Science Citation Index SCI Expanded (Web of Science) 1900 to 30 August 2016
Conference Proceedings Citation Index (Web of Science) 1900 to 1 September 2016
Search strategy:
#1 (melanom* or nonmelanom* or non-melanoma* or melanocyt* or non-melanocyt* or nonmelanocyt* or keratinocyt*)
#2 (basalioma*)
#3 ((skin) near/2 (cancer* or carcinoma or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or lesion*
or malignan* or nodule*))
#4 ((basal) near/2 (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#5 ((pigmented) near/2 (lesion* or mole* or nevus or nevi or naevus or naevi or skin))
#6 (nmsc or BCC or NMSC or keratinocy*)
#7 ((squamous cell (cancer* or carcinoma* or mass or masses or tumour* or tumor* or neoplasm* or adenoma* or epithelioma* or
lesion* or malignan* or nodule*))
#8 (skin or epiderm* or cutaneous)
#9 #8 AND #7
#10 #9 OR #6 OR #5 OR #4 OR #3 OR #2 OR #1
#11 ((dermoscop* or dermatoscop* or photomicrograph* or epiluminescence or confocal or “incident light” or “surface microscop*”
or “visual inspect*” or “physical exam*” or 3 point or three point or pattern analy* or ABCDE or menzies or 7 point or seven point
or dermoscop* or dermatoscop* or AI or artificial or computer aided or computer assisted or neural network* or Molemax or image
process* or automatic classif* or image analysis or siascope or optical scan* or Aura or melafind or simsys or molemate or solarscan or
vivascope or confocal microscop* or high ultraso* or canine detect* or cellphone* or mobile* or phone* or smartphone or dermoscan
or skinvision or dermlink or spotcheck or spot check or mole detective or mole map* or total body or exfoliative psychology or digital
or image software or optical coherence or teledermatology or telederm* or teledermoscop* or teledermatoscop* or computer diagnos*
or sentinel))
#12 ((nevisense or HFUS or impedance spectroscopy or history taking or patient history or naked eye or skin exam* or physical exam*
or ugly duckling or UD sign* or physician* exam* or physical exam* or ABCDE or clinical accuracy or general practice or confocal
microscop* or clinical competence or diagnostic algorithm* or checklist* or virtual image* or volatile organic or VOC or dog* or gene
expression or reflex transmission or thermal imag* or elastography))
#13 #11 or #12
#14 ((PET or CT or FDG or deoxyglucose or deoxy-glucose or fluorodeoxy* or radiopharma* or CATSCAN or positron emission or
computer assisted or nuclear magnetic or MRI or FMRI or NMRI or scintigraph* or echograph* or Doppler or sonograph* or ultraso*
or magnetic reson*))
#15 ((stage* or staging or metast* or recurrence or sensitivity or specificity or false negative* or thickness*))
#16 #14 AND #15
#17 #16 OR #13
#18 #10 AND #17
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Refined by: DOCUMENT TYPES: (MEETING ABSTRACT OR PROCEEDINGS PAPER)
Appendix 3. Full-text inclusion criteria
The title and abstract screening led to the retrieval of a large number of full-text journal papers and conference abstracts from which
to complete the four sets of test accuracy reviews and the intervention review. The systematic reviews were largely be carried out
sequentially, beginning with the reviews of tests for melanoma diagnosis; however, the full-text papers needed to be screened at the
beginning of the Programme Grant and papers meeting the inclusion criteria tagged accordingly per review.
The table below summarises the inclusion criteria to be applied; these were transferred to an Excel spreadsheet or Google Forms so that
pertinent information could be recorded about each eligible study and reasons for exclusion recorded about each ineligible study.
Criterion Inclusion Exclusion
Study design For diagnostic and staging reviews
• Any study for which a 2×2 contingency table
can be extracted, e.g.
◦ diagnostic case-control studies
◦ ’cross-sectional’ test accuracy study with
retrospective or prospective data collection
◦ studies where estimation of test accuracy
was not the primary objective but test results for
both index and reference standard were available
◦ RCTs of tests or testing strategies where
participants were randomised between index tests
and all undergo a reference standard (i.e. accuracy
RCTs)
• < 5 melanoma cases (diagnosis reviews)
• < 10 participants (staging reviews)
• Studies developing new criteria for diagnosis
unless a separate ’test set’ of images were used to
evaluate the criteria (mainly digital dermoscopy)
• Studies using ’normal’ skin as controls
• Letters, editorials, comment papers, narrative
reviews
• Insufficient data to construct a 2×2 table
Target condition • Melanoma
• Keratinocyte skin cancer (or non-melanoma
skin cancer)
◦ BCC or epithelioma
◦ cSCC
• Studies exclusively conducted in children
• Studies of non-cutaneous melanoma or SCC
Population For diagnostic reviews
• Adults with a skin lesion suspicious for
melanoma, BCC, or cSCC (other terms included
pigmented skin lesion/nevi, melanocytic,
keratinocyte, etc.)
• Adults at high risk of developing melanoma
skin cancer, BCC, or cSCC
For staging reviews
• Adults with a diagnosis of melanoma or cSCC
undergoing tests for staging of lymph nodes or
distant metastases or both
• People suspected of other forms of skin cancer
• Studies conducted exclusively in children
Index tests For diagnosis
• Visual inspection/clinical examination
• Dermoscopy/dermatoscopy
• Teledermoscopy
• Smartphone/mobile phone applications
• Sentinel lymph biopsy for therapeutic rather
than staging purposes
• Tests to determine melanoma thickness
• Tests to determine surgical margins/lesion
borders
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(Continued)
• Digital dermoscopy/artificial intelligence
• Confocal microscopy
• Ocular coherence tomography
• Exfoliative cytology
• High-frequency ultrasound
• Canine odour detection
• DNA expression analysis/gene chip analysis
• Other
For staging
• CT
• PET
• PET-CT
• MRI
• Ultrasound +/FNAC
• SLNB +/high-frequency ultrasound
• Other
Any test combination and in any order
Any test positivity threshold
Any variation in testing procedure (e.g. radioisotope
used)
• Tests to improve histopathology diagnose
• LND
Reference standard For diagnostic studies
• Histopathology of the excised lesion
• Clinical follow-up of non-excised/benign-
appearing lesions with later histopathology if
suspicious
• Expert diagnosis (studies should not be
included if expert diagnosis is the sole reference
standard)
For studies of imaging tests for staging
• Histopathology (via LND or SLNB)
• Clinical/radiological follow-up
• A combination of the above
For studies of SLNB accuracy for staging
• LND of both SLN+ and SLn participants to
identify all diseased nodes
• LND of SLN+ participants and follow-up of
SLN participants to identify a subsequent nodal
recurrence in a previously investigated nodal basin
For diagnostic studies
• Exclude if any disease positive participants have
diagnosis unconfirmed by histology
• Exclude if > 50% of disease-negative
participants have diagnosis confirmed by expert
opinion with no histology or follow-up
• Exclude studies of referral accuracy, i.e.
comparing referral decision with expert diagnosis,
unless evaluations of teledermatology or mobile
phone applications
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma; CT: computed tomography; FNAC: fine needle aspiration
cytology; LND: lymph node dissection; MRI: magnetic resonance imaging; PET: positron emission tomography; PET-CT: positron
emission tomography computed tomography; RCT: randomised controlled trial; SCC: squamous cell carcinoma; SLN+: positive
sentinel lymph node; SLn: negative sentinel lymph node; SLNB: sentinel lymph node biopsy
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Appendix 4. Quality assessment (based on QUADAS-2)
The following tables use text that was originally published in the QUADAS-2 tool by Whiting and colleagues (Whiting 2011).
Item Response (delete as required)
Participant selection (1) -risk of bias
1) Was a consecutive or random sample of participants or images
enrolled?
Yes - if paper states consecutive or random
No - if paper describes other method of sampling
Unclear - if participant sampling not described
2) Was a case-control design avoided? Yes - if consecutive or random or case-control design clearly not
used
No - if study described as case-control or describes sampling spe-
cific numbers of participants with particular diagnoses
Unclear - if not described
3) Did the study avoid inappropriate exclusions?
• Lesions not excluded on basis of disagreement between
evaluators
Yes - if inappropriate exclusions were avoided
No - if lesions were excluded that might affect test accuracy, e.g.
where disagreement between evaluators was observed
Unclear - if not clearly reported
4) For between-person comparative studies only (i.e. allocating
different tests to different study participants):
• A) were the same participant selection criteria used for
those allocated to each test?
• B) was the potential for biased allocation between tests
avoided through adequate generation of a randomised sequence?
• C) was the potential for biased allocation between tests
avoided through concealment of allocation prior to assignment?
For A)
• Yes - if same selection criteria were used for each index test,
No - if different selection criteria were used for each index test,
Unclear - if selection criteria per test were not described, N/A -
if only 1 index test was evaluated or all participants received all
tests.
For B)
• Yes - if adequate randomisation procedures are described,
No - if inadequate randomisation procedures are described,
Unclear - if the method of allocation to groups is not described
(a description of ’random’ or ’randomised’ is insufficient), N/A -
if only 1 index test was evaluated or all participants received all
tests.
For C)
• Yes - if appropriate methods of allocation concealment are
described, No - if appropriate methods of allocation concealment
are not described, Unclear - if the method of allocation
concealment is not described (sufficient detail to allow a definite
judgement is required), N/A - if only 1 index test was evaluated.
Could the selection of participants have introduced bias?
For non-comparative and within-person comparative studies
1. If answers to all of questions 1), 2), and 3) ’Yes’
2. If answers to any 1 of questions 1), 2), or 3) ’No’
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’
For between-person comparative studies
1. If answers to all of questions 1), 2), 3), and 4) ’Yes’
2. If answers to any 1 of questions 1), 2), 3), or 4) ’No’
For non-comparative and within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For between-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
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3. If answers to any 1 of questions 1), 2), 3), or 4) ’Unclear’
Participant selection (1) -concerns regarding applicability
1) Are the included participants and chosen study setting appro-
priate to answer the review question, i.e. are the study results gen-
eralisable?
This item is not asking whether exclusion of certain participant
groups might bias the study’s results (as in ’Risk of bias’ above)
, but is asking whether the chosen study participants and setting
are appropriate to answer our review question
A) For studies that will contribute to the analysis of partici-
pants with suspected melanoma
Yes - if study participants appear to be representative of those
who might be referred for further investigation. Studies focusing
on participant populations with equivocal findings on clinical or
dermoscopic (or both) investigation are considered representative
of those who could receive OCT in practice
No - if study participants appear to be unrepresentative of usual
practice, e.g. if a particularly high proportion of participants have
been self-referred or referred for cosmetic reasons. Other factors
to consider include severity of disease, demographic features, pres-
ence of differential diagnosis or comorbidity, setting of the study,
and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
B) For studies that will contribute to the analysis of partici-
pants with suspected keratinocyte cancers
Yes - if study participants appear to be representative of those
who might be referred for further investigation. Studies focusing
on participant populations with equivocal findings on clinical or
dermoscopic (or both) investigation are considered representative
of those who could receive OCT in practice
No - if study participants appear to be unrepresentative of usual
practice, e.g. if a particularly high proportion of participants have
been self-referred or referred for cosmetic reasons. Other factors
to consider include severity of disease, demographic features, pres-
ence of differential diagnosis or comorbidity, setting of the study,
and previous testing protocols
Unclear - if insufficient details are provided to determine the
generalisability of study participants
2) Did the study avoid including participants with multiple le-
sions?
Yes - if the difference between the number of included lesions and
number of included participants is less than 5%
No - if the difference between the number of included lesions and
number of included participants is greater than 5%
Unclear - if it is not possible to assess
Is there concern that the included participants do not match the
review question?
1. If the answer to question 1) or 2) ’Yes’
2. If the answer to question 1) or 2) ’No’
3. If the answer to question 1) or 2) ’Unclear’
1. Concern is low
2. Concern is high
3. Concern is unclear
Index test (2) -risk of bias (to be completed per test evaluated)
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1) Was the index test or testing strategy result interpreted without
knowledge of the results of the reference standard?
Yes - if index test described as interpreted without knowledge of
reference standard result or, for prospective studies, if index test is
always conducted and interpreted prior to the reference standard
No - if index test described as interpreted in knowledge of reference
standard result
Unclear - if index test blinding is not described
2) Was the diagnostic threshold at which the test was considered
positive (i.e. melanoma, BCC or cSCC present) prespecified?
Yes - if threshold was prespecified (i.e. prior to analysing study
results)
No - if threshold was not prespecified
Unclear - if not possible to tell whether or not diagnostic threshold
was prespecified
3) For within-person comparisons of index tests or testing strate-
gies (i.e. > 1 index test applied per participant): was each index
test result interpreted without knowledge of the results of other
index tests or testing strategies?
Yes - if all index tests were described as interpreted without knowl-
edge of the results of the others
No - if the index tests were described as interpreted in the knowl-
edge of the results of the others
Unclear - if it is not possible to tell whether knowledge of other
index tests could have influenced test interpretation
N/A - if only 1 index test was evaluated.
Could the conduct or interpretation of the index test have intro-
duced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1) and 2) ’Yes’
2. If answers to either questions 1) or 2) ’No’
3. If answers to either questions 1) or 2) ’Unclear’
For within-person comparative studies
• If answers to all questions 1), 2), and 3) for any index test
’Yes’
• If answers to any 1 of questions 1), 2), or 3) for any index
test ’No’
• If answers to any 1 of questions 1), 2), or 3) for any index
test ’Unclear’
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
Index test (2) -concern about applicability
1) Was the test applied and interpreted in a clinically applicable
manner?
Yes - if a single clinician interpreted the scan with the participant
present, and made the diagnosis alone
No - If the accuracy 2×2 data are based on a mean of multiple
observers, or consensus across observers; OR if the scan was inter-
preted using the image alone, as opposed to with the participant
present
Unclear - if insufficient information was reported.
2) Were thresholds or criteria for diagnosis reported in sufficient
detail to allow replication?
Study results can only be reproduced if the diagnostic threshold is
described in sufficient detail. This item applies equally to studies
Yes - if the criteria for diagnosis of melanoma, BCC, or cSCC
were reported in sufficient detail to allow replication
No - if the criteria for diagnosis of melanoma, BCC, or cSCC
were not reported in sufficient detail to allow replication
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using pattern recognition and those using checklists or algorithms
to aid test interpretation
Unclear - if some but not sufficient information on criteria for
diagnosis to allow replication were provided
3) Was the test interpretation carried out by an experienced ex-
aminer?
Yes - if the test was interpreted by 1 or more speciality-accredited
dermatologists, or by examiners of any clinical background with
special interest in dermatology and with any formal training in
the use of the test,
No - if the test was not interpreted by an experienced examiner
(see above),
Unclear - if the experience of the examiner(s) was not reported
in sufficient detail to judge or if examiners described as ’Expert’
with no further detail given,
N/A - if system-based diagnosis, i.e. no observer interpretation
Is there concern that the index test, its conduct, or interpretation
differ from the review question?
1. If answers to questions 1), 2), and 3) ’Yes’
2. If answers to questions 1), 2), or 3) ’No’
3. If answers to questions 1), 2), or 3) ’Unclear’
1. Concern is low
2. Concern is high
3. Concern is unclear
Reference standard (3) -risk of bias
1) Is the reference standard likely to correctly classify the target
condition?
A) Disease-positive - 1 or more of the following:
• histological confirmation of melanoma, BCC, or cSCC
following biopsy or lesion excision;
• clinical follow-up of benign-appearing lesions for at least 6
(or 3 for cSCC) months following the application of the index
test, leading to a histological diagnosis of BCC or cSCC.
B) Disease-negative - 1 or more of the following:
• histological confirmation of absence of melanoma, BCC, or
cSCC following biopsy or lesion excision in at least 80% of
disease-negative participants;
• clinical follow-up of benign-appearing lesions for a
minimum of 6 months (or 3 for cSCC) following the index test
in up to 20% of disease-negative participants.
A) Disease-positive
Yes - if all participants with a final diagnosis of melanoma, BCC,
or cSCC underwent 1 of the listed reference standards
No - if a final diagnosis of melanoma, BCC, or cSCC for any
participant was reached without histopathology
Unclear - if the method of final diagnosis was not reported for
any participant with a final diagnosis of BCC or cSCC or if the
length of clinical follow-up used was not clear or if a clinical
follow-up reference standard was reported in combination with
a participant-based analysis and it was not possible to determine
whether the detection of a malignant lesion during follow-up is
the same lesion that originally tested negative on the index test
B) Disease-negative
Yes - if at least 80% of benign diagnoses were reached by histology
and up to 20% were reached by clinical follow-up for a minimum
of 6 (or 3) months following the index test
No - ifmore than20%of benigndiagnoseswere reachedby clinical
follow-up for a minimum of 6 (or 3) months following the index
test or if clinical follow-up period was less than 6 (or 3) months
Unclear - if the method of final diagnosis was not reported for
any participant with benign diagnosis
2) Were the reference standard results interpreted without knowl-
edge of the results of the index test?
Please score this item for all studies even though histopathology
interpretation is usually conducted with knowledge of the clinical
diagnosis (from visual inspection or dermoscopy or both).We will
Yes - if the reference standard diagnosis was reached blinded to
the index test result
No - if the reference standard diagnosis was reached with knowl-
edge of the index test result
Unclear - if blinded reference test interpretation was not clearly
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deal with this by not including the response to this item in the
’Risk of bias’ assessment for these tests. For reviews of all other
tests, this item will be retained
reported
Could the reference standard, its conduct, or its interpretation
have introduced bias?
For visual inspection/dermoscopy evaluations
1. If answer to question 1) ’Yes’
2. If answer to question 1) ’No’
3. If answer to question 1) ’Unclear’
For all other tests
1. If answers to questions 1) and 2) ’Yes’
2. If answers to questions 1) or 2) ’No’
3. If answers to questions 1) or 2) ’Unclear’
For visual inspection/dermoscopy evaluations
1. Risk is low
2. Risk is high
3. Risk is unclear
For all other tests
1. Risk is low
2. Risk is high
3. Risk is unclear
Reference standard (3) -concern about applicability
1) Expert opinion (with no histological confirmation) was not
used as a reference standard
’Expert opinion’ means diagnosis based on the standard clinical
examination, with no histology or lesion follow-up
Yes - if expert opinion was not used as a reference standard for
any participant
No - if expert opinion was used as a reference standard for any
participant
Unclear - if not clearly reported
2) Was histology interpretation carried out by an experienced
histopathologist or by a dermatopathologist?
Yes - if histology interpretation was reported to be carried out by
an experienced histopathologist or dermatopathologist
No - if histology interpretation was reported to be carried out by
a less experienced histopathologist
Unclear - if the experience/qualifications of the pathologist were
not reported
Is there concern that the target condition as defined by the refer-
ence standard does not match the review question?
1. If answers to all questions 1) and 2) ’Yes’
2. If answers to either question 1) or 2) ’No’
3. If answers to either question 1) or 2)
1. Concern is low
2. Concern is high
3. Concern is unclear
Flow and timing (4): risk of bias
1) Was there an appropriate interval between index test and ref-
erence standard?
A) For histopathological reference standard, was the interval be-
tween index test and reference standard ≤ 1 month?
B) If the reference standard includes clinical follow-up of border-
line/benign-appearing lesions, was there at least 6 (or 3) months’
follow-up following application of index test(s) for studies of
melanoma, BCC, (or cSCC)?
A)
Yes - if study reports ≤ 1 month between index and reference
standard
No - if study reports > 1 month between index and reference
standard
Unclear - if study does not report interval between index and
reference standard
B)
Yes - if study reports ≥ 6 (or 3 for cSCC) months’ follow-up
No - if study reports < 6 (or 3 for cSCC) months’ follow-up
Unclear - if study does not report length of clinical follow-up
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2) Did all participants receive the same reference standard? Yes - if all participants underwent the same reference standard
No - if more than 1 reference standard was used
Unclear - if not clearly reported
3) Were all participants included in the analysis? Yes - if all participants were included in the analysis.
No - if some participants were excluded from the analysis.
Unclear - if not clearly reported
4) For within-person comparisons of index tests
Was the interval between application of index tests ≤ 1 month?
Yes - if study reports ≤ 1 month between index tests
No - if study reports > 1 month between index tests
Unclear - if study does not report interval between index tests
Could the participant flow have introduced bias?
For non-comparative and between-person comparison studies
1. If answers to questions 1), 2), and 3) ’Yes’
2. If answers to any 1 of questions 1), 2), or 3) ’No’
3. If answers to any 1 of questions 1), 2), or 3) ’Unclear’
For within-person comparative studies
1. If answers to all questions 1), 2), 3), and 4) ’Yes’
2. :If answers to any 1 of questions 1), 2), 3), or 4) ’No’
3. :If answers to any 1 of questions 1), 2), 3), or 4) is ’Unclear’
For non-comparative and between-person comparison studies
1. Risk is low
2. Risk is high
3. Risk is unclear
For within-person comparative studies
1. Risk is low
2. Risk is high
3. Risk is unclear
BCC: basal cell carcinoma; cSCC: cutaneous squamous cell carcinoma
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AK: actinic keratosis; BCC: basal cell carcinoma; BD: Bowen’s disease; BN: benign naevus; CCS: case-control study; cSCC: cuta-
neous squamous cell carcinoma; HD-OCT: high-definition optical coherence tomography; MiS: melanoma in situ; MM: malignant
melanoma; MSL: melanocytic skin lesion; NC: non-comparative study design; NR: not reported; OCT: optical coherence tomogra-
phy; P-CS: prospective case series; PSL: pigmented skin lesion; SK: seborrhoeic keratosis; VI: visual inspection; WPC: within-person
comparison study design.
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Due to the small number of studies available, we produced a single review that evaluated the accuracy of OCT in all skin cancers; this
replaced the two reviews intended in the protocols to address cutaneous melanoma and keratinocyte cancers.
For the detection of melanomas, we changed primary objectives and primary target condition from detection of cutaneous invasive
melanoma alone to the detection of cutaneous invasive melanoma and atypical intraepidermal melanocytic variants, as the latter is
more clinically relevant to the practicing clinician. These were reported alongside the original primary objectives and primary target
conditions for the review of keratinocyte cancers. The detection of the target condition of invasive melanoma alone was instead included
as a secondary objective. Due to the fact that a single review covering both melanoma and keratinocyte skin cancers was conducted,
the third definition of the target condition as defined in the melanoma protocol was adopted and the following definition from the
keratinocyte protocol was dropped “the target condition will include any skin lesion requiring excision. Studies reporting data for
keratinocyte skin cancer combined, and not differentiated according to BCC or cSCC, will be included in this analysis, along with any
melanoma, or rare skin cancer (e.g. Merkel or amelanotic melanoma) that may be detected. In situ cancers or actinic keratosis will not
be considered disease positive.”
Inclusion criteria amended to remove inclusion of participants: “at high risk of developing melanoma, including those with a family
history or previous history of melanoma skin cancer, atypical or dysplastic naevus syndrome, or genetic cancer syndromes” and “at high
risk of developing BCC or cSCC, including those with a family history or previous history of skin cancer or genetic cancer syndromes,
such as basal cell naevus (Gorlin) syndrome” as these are not target populations for OCT use.
We amended the text to clarify that studies available only as conference abstracts would be excluded from the review unless full
papers could be identified; studies available only as conference abstracts do not allow a comprehensive assessment of study methods or
methodological quality.
To improve clarity of methods, this text from the protocol, “We will include studies developing new algorithms or methods of diagnosis
(i.e. derivation studies), if they use a separate independent ’test set’ of participants or images to evaluate the new approach. We will
also include studies using other forms of cross validation, such as ’leave-one-out’ cross-validation (Efron 1983). We will note for future
reference (but not extract), any data on the accuracy of lesion characteristics individually, e.g. the presence or absence of a pigment
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network or detection of asymmetry” has been replaced with the following: “We included studies developing new algorithms or methods
of diagnosis (i.e. derivation studies), were included if they:
• used a separate independent ’test set’ of participants or images to evaluate the new approach; or
• investigated lesion characteristics that had previously been suggested as associated with melanoma, BCC or cSCC and the study
reported accuracy based on the presence or absence of particular combinations of characteristics.
We excluded studies if they:
• used a statistical model to produce a data driven equation, or algorithm based on multiple diagnostic features, with no separate
test set;
• used cross-validation approaches such as ’leave-one-out’ cross-validation (Efron 1983);
• evaluated the accuracy of the presence or absence of individual OCT characteristics or morphological features, with no overall
diagnosis of malignancy.”
We proposed to supplement the database searches by searching the annual meetings of appropriate organisations (e.g. British Association
of Dermatologists Annual Meeting, American Academy of Dermatology Annual Meeting, European Academy of Dermatology and
Venereology Meeting, Society for Melanoma Research Congress, World Congress of Dermatology, European Association of Dermato
Oncology); however, due to volume of evidence retrieved from database searches and time restrictions, we were unable to do this.
For quality assessment, the QUADAS-2 tool was further tailored according to the review topic.
Due to lack of data, we could not perform the following analyses: estimation of accuracy in primary presentation populations, restriction
to analysis of per patient data, comparison of accuracy using diagnosis of stored images (image-based) with in-person diagnosis, or
sensitivity analyses.
We planned three additional heterogeneity investigations relating to population characteristics than those listed in the protocol (par-
ticipant population: primary/secondary/specialist unit; lesion type: any pigmented/melanocytic; inclusion of multiple lesions per par-
ticipant); however, we could not perform these investigations due to insufficient data.
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